Benzimidazolone derived inhibitors of bcl6

Abstract

The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

Description

BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6INTRODUCTION

[0001] The present invention relates to certain compounds that function as inhibitors of BCL6 (B-cell lymphoma 6) activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.BACKGROUND OF THE INVENTION

[0002] BCL6 is a zinc finger transcription repressor that plays a key role in the formation and development of germinal centres, in which B cells undergo somatic hypermutation and recombination of the immunoglobulin genes, in order to generate diversity in antibodies against a variety of foreign antigens (Dent et al., Science, 1997, 276, 589-592). BCL6 allows the proliferation of antibody producing B cells by repressing genes involved in DNA damage response, cell cycle arrest and apoptosis. BCL6 mediates this repression by recruiting the corepressor proteins SMRT, NCoR and BCoR to an extended groove motif that forms along the dimer interface of the BCL6 BTB (BR-C, Ttk and Bab) domain (Ahmad et al., Mol Cell, 2003, 12, 1551-1564; Ghetu et al., Mol Cell, 2008, 29, 384-391). Genetic upregulation of the BCL6 gene, as seen in many lymphomas, leads to malignant B cell proliferation (Hatzi & Melnick, Trends Mol Med, 2014, 20, 343-352). Therefore, there exists a need to develop agents that inhibit the tumourigenic effects of BCL6, either by selectively binding to the BTB domain and preventing corepressor recruitment, or by binding to the BTB domain and inducing protein degradation (Kerres et al. Cell Rep., 2017, 20, 2860-2875).SUMMARY OF THE INVENTION

[0003] According to a first aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.

[0004] According to a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

[0005] According to a further aspect of the present invention, there is provided a method of inhibiting BCL6 activity, in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein.

[0006] According to a further aspect of the present invention, there is provided a method of inhibiting cell proliferation, in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0007] According to a further aspect of the present invention, there is provided a method of treating a disease or disorder in which BCL6 activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0008] According to a further aspect of the present invention, there is provided a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0009] According to a further aspect of the present invention, there is provided a method of treating cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0010] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in therapy.

[0011] According to a further aspect of the present invention, there is provided a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative condition.

[0012] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the treatment of cancer. In a particular embodiment, the cancer is human cancer.

[0013] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the inhibition of BCL6 activity.

[0014] According to a further aspect of the present invention, there is provided a compound,or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the treatment of a disease or disorder in which BCL6 activity is implicated.

[0015] According to a further aspect of the present invention, there is provided the use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a proliferative condition.

[0016] Suitably, the proliferative disorder is cancer, suitably a human cancer (for example haematological cancers such as lymphomas (including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL) and angioimmunoblastic T-cell lymphoma (AITL)), leukaemias (including acute lymphoblastic leukaemia (ALL) and chronic myeloid leukaemia (CML)) and multiple myeloma, and solid tumours (including glioma, breast cancer, non-small cell lung cancer (NSCLC) and squamous cell carcinomas (SCC) (including SCC of the head and neck, oesophagus, lung and ovary))).

[0017] According to a further aspect of the present invention, there is provided the use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of cancer.

[0018] According to a further aspect of the present invention, there is provided a use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the inhibition of BCL6 activity.

[0019] According to a further aspect of the present invention, there is provided a use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a disease or disorder in which BCL6 activity is implicated.

[0020] According to a further aspect of the present invention, there is provided a process for preparing a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.

[0021] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, obtainable by, or obtained by, or directly obtained by a process of preparing a compound as defined herein.

[0022] According to a further aspect of the present invention, there are provided novel intermediates as defined herein which are suitable for use in any one of the synthetic methods set out herein.

[0023] Features, including optional, suitable, and preferred features in relation to one aspect of the invention may also be features, including optional, suitable and preferred features in relation to any other aspect of the invention.DETAILED DESCRIPTION OF THE INVENTIONDefinitions

[0024] Unless otherwise stated, the following terms used in the specification and claims have the following meanings set out below.

[0025] It is to be appreciated that references to "treating" or "treatment" include prophylaxis as well as the alleviation of established symptoms of a condition. "Treating" or "treatment" of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.

[0026] A "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.

[0027] In this specification the term "alkyl" includes both straight and branched chain alkyl groups. References to individual alkyl groups such as "propyl" are specific for the straight chain version only and references to individual branched chain alkyl groups such as "isopropyl" are specific for the branched chain version only. For example, "(1-6C)alkyl" includes (1- 4C)alkyl, (1-3C)alkyl, propyl, isopropyl and f-butyl.

[0028] The term "(m-nC)" or "(m-nC) group" used alone or as a prefix, refers to any group having m to n carbon atoms.

[0029] An "alkylene" group is an alkyl group that is positioned between and serves to connect two other chemical groups. Thus, "(1-6C)alkylene" means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, for example, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), 2-methylpropylene (-CH2CH(CH3)CH2-), pentylene (- CH2CH2CH2CH2CH2-), and the like.

[0030] "(3-10C)cycloalkyl" means a hydrocarbon ring containing from 3 to 10 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and bicyclo[2.2.1]heptyl.

[0031] "(3-10C)cycloalkenyl" means a hydrocarbon ring containing from 3 to 10 carbon atoms and at least one double bond, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, such as 3-cyclohexen-1-yl, or cyclooctenyl.

[0032] The term "halo" or "halogeno" refers to fluoro, chloro, bromo and iodo, suitably fluoro, chloro and bromo, more suitably, fluoro and chloro.

[0033] The term "heterocyclyl", "heterocyclic" or "heterocycle" means a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s). Monocyclic heterocyclic rings contain from about 3 to 12 (suitably from 3 to 7) ring atoms, with from 1 to 5 (suitably 1 , 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. Bicyclic heterocycles contain from 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems. Examples of heterocyclic groups include cyclic ethers such as oxiranyl, oxetanyl, tetrahydrofuranyl, dioxanyl, and substituted cyclic ethers. Heterocycles containing nitrogen include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, and the like. Typical sulfur containing heterocycles include tetrahydrothienyl, dihydro-1 ,3-dithiol, tetrahydro-2 / - / -thiopyran, and hexahydrothiepine. Other heterocycles include dihydro-oxathiolyl, tetrahydro-oxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO2 groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl such as tetrahydrothiene 1 , 1 -dioxide and thiomorpholinyl 1 , 1 -dioxide. A suitable value for a heterocyclyl group which bears 1 or 2 oxo (=0) or thioxo (=S) substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Particular heterocyclyl groups are saturated monocyclic 3 to 7 membered heterocyclyls containing 1 , 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, for example azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1 , 1 -dioxide, thiomorpholinyl, thiomorpholinyl 1 , 1 -dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As the skilled person would appreciate, any heterocycle may be linked to another group via any suitable atom, such as via a carbon or nitrogen atom. However, reference herein to piperidino or morpholino refers to a piperidin-1- yl or morpholin-4-yl ring that is linked via the ring nitrogen.

[0034] By "bridged ring systems" is meant ring systems in which two rings share more than two atoms, see for example Advanced Organic Chemistry, by Jerry March, 4thEdition, WileyInterscience, pages 131-133, 1992. Examples of bridged heterocyclyl ring systems include, aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza- bicyclo[3.2.1]octane and quinuclidine.

[0035] By "spiro bi-cyclic ring systems" we mean that the two ring systems share one common spiro carbon atom, i.e. the heterocyclic ring is linked to a further carbocyclic or heterocyclic ring through a single common spiro carbon atom. Examples of spiro ring systems include 6- azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptanes, 2-oxa-6- azaspiro[3.3]heptanes, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 2-oxa-7- azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.5]nonane.

[0036] The term "heteroaryl" or "heteroaromatic" means an aromatic mono-, bi-, or polycyclic ring incorporating one or more (for example 1-4, particularly 1 , 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur. The term heteroaryl includes both monovalent species and divalent species. Examples of heteroaryl groups are monocyclic and bicyclic groups containing from five to twelve ring members, and more usually from five to ten ring members. The heteroaryl group can be, for example, a 5- or 6-membered monocyclic ring or a 9- or 10- membered bicyclic ring, for example a bicyclic structure formed from fused five and six membered rings or two fused six membered rings. Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically the heteroaryl ring will contain up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.

[0037] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1 ,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl, 1 H-pyrazolo[4,3-d]-oxazolyl,4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2, 1-b]thiazolyl, imidazo[1 ,2-b][1 ,2,4]triazinyl. "Heteroaryl" also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a non-aromatic, saturated or partially saturated ring, provided at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or sulfur. Examples of partially aromaticheteroaryl groups include for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo- 1 ,2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 2,3-dihydro- benzo[1 ,4]dioxinyl, benzo[1 ,3]dioxolyl, 2,2-dioxo-1 ,3-dihydro-2-benzothienyl, 4,5,6,7- tetrahydrobenzofuranyl, indolinyl, 1 ,2,3,4-tetrahydro-1 ,8-naphthyridinyl,1 ,2,3,4-tetrahydropyrido[2,3- 5]pyrazinyl and 3,4-dihydro-2 / - / -pyrido[3,2-£>][1 ,4]oxazinyl.

[0038] Examples of five membered heteroaryl groups include but are not limited to pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.

[0039] Examples of six membered heteroaryl groups include but are not limited to pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl.

[0040] A bicyclic heteroaryl group may be, for example, a group selected from:a benzene ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms;a pyridine ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms;a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;a pyrrole ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms;a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiophene ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms; a furan ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms;a cyclohexyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1 , 2 or 3 ring heteroatoms; anda cyclopentyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1 , 2 or 3 ring heteroatoms.

[0041] Particular examples of bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzfuranyl, benzthiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adeninyl, guaninyl), indazolyl, benzodioxolyl and pyrazolopyridinyl groups.

[0042] Particular examples of bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolizinyl, benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl and pteridinyl groups.

[0043] The term "aryl" means a cyclic or polycyclic aromatic ring having from 5 to 12 carbon atoms. The term aryl includes both monovalent species and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like. In a particular embodiment, an aryl is phenyl.

[0044] The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted. The term "wherein a / any CH, CH2, CH3 group or heteroatom (i.e. NH) within a R1group is optionally substituted" suitably means that (any) one of the hydrogen radicals of the R1group is substituted by a relevant stipulated group.

[0045] Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

[0046] The phrase "compound of the invention" means those compounds which are disclosed herein, both generically and specifically.Compounds of the invention

[0047] In one aspect, the present invention relates to compounds, or pharmaceutically acceptable salts, hydrates or ral formula (I), shown below:Formula (I)wherein:Xi is selected from N or CRawherein Rais selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2-4C)alkenyl, (2-4C)alkynyl, nitro, cyano or NRbRc, wherein Rband Rcare independently selected from hydrogen or (1-2C)alkyl;X2 is selected from N or CRd, wherein Rdis selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy;R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo;Y is absent or O, S, SO, S02, N(Re), C(O), C(0)0, OC(O), C(0)N(Re), N(Re)C(0), N(Re)C(0)N(Rf), N(Re)C(0)0, OC(0)N(Re), S(0)2N(Re), or N(Re)SC>2, wherein Reand Rfare each independently selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(0)R9, C(0)OR9, OC(0)R9, C(0)N(R9)Rh, N(R9)C(0)Rh, S(0)yR9(where y is 0, 1 or 2), S02N(R9)Rh, N(R9)S02R9, Si^XR^R1or (CH2)zNR9Rh(where z is 1 , 2 or 3); wherein R9,Rhand R' are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R9and Rhcan be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring which is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano or hydroxy;R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)R', SO2R1, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R1and Rmare independently selected from hydrogen or (1-4C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rn), N(Rn)C(0), S(0)2N(Rn), or N(Rn)S02, wherein Rnis selected from hydrogen or (1- 2C)alkyl;l_2 is absent or (1 -2C)alkylene; andZ2is hydrogen, (1 -6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 - 4C)haloalkoxy, (1 -4C)alkoxy, (1 -4C)alkylamino, amino, cyano, nitro, hydroxy, C(0)R°, C(0)OR°, OC(0)R°, C(0)N(R°)RP, N R°C(0)RP, wherein R° and RP are independently selected from hydrogen or (1 -4C)alkyl; andR8is selected from (1 -2C)alkyl, -C(0)ORQ, ORQ, -C(0)N RQ, N RQRR, phenyl or a 5-membered heteroaryl, wherein RQand RRare independently selected from hydrogen or (1 -2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 -2C)haloalkoxy, (1 - 2C)alkoxy, (1 -2C)alkylamino, amino, cyano or hydroxyl; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 4 to 6 membered cydoalkyi or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, (1-4C)haloalkyl, (1-4C)hydroxyalkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1-4C)alkyl, R101and R102are eachindependently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl; andlected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H orCF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CFs;R10is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR 1 (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(Rs)S02, wherein Rsand R< are each independently selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRuRvor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; andWz is aryl, heteroaryl, 4- to 7-membered heterocyclyl, 3- to 6-membered carbocycyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C^R"3, COORxa, C(0)NRxaRxbor NR^R^, wherein R*3and R* are each independently selected from hydrogen or (1-4C)alkyl; and wherein each aryl, heteroaryl, 4- to 7-membered heterocyclyl or 3- to 6-membered carbocycyl is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, amino, cyano or hydroxy;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc. Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), NiR^CiOJNiR3"), N(Rw)C(0)0, OC(0)N(Rw), S(0)2N(Rw), N(Rw)S02, wherein Rwand Rxare each independently selected from hydrogen or (1- 4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3;Xf and Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1- 2C)haloalkyl or (1-2C)haloalkoxy;Xh, X and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;with the proviso that:(i) when R3is a group of Formula B, no more than two of Xc, Xd and Xeare nitrogen;(ii) when R3is a group of Formula C, no more than three of Xf, Xg, Xh, X and Xj are nitrogen;(iii) when Xi and X2are CH, R1and R2are hydrogen or methyl, R3is a group of Formula A, Xais N, Xb is CH and R9is methyl or fluoro, R10is not a methylsulfonylaminophenyl or an aminosulfonylphenyl;(iv) when Y3 is NH, each of R1and R2are not hydrogen or methyl; and(v) the compound is not one of the following:

[0048] In an embodiment, the present invention relates to compounds, or pharmaceutically acceptable salts, hydrates or ral formula (I), shown below:Formula (I)wherein:Xi is selected from N or CRawherein Rais selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2- 4C)alkenyl, (2-4C)alkynyl, nitro, cyano or NRbRc, wherein Rband Rcare independently selected from hydrogen or (1-2C)alkyl;X2 is selected from N or CRd, wherein Rdis selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy;R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo;Y is absent or O, S, SO, S02, N(Re), C(O), C(0)0, OC(O), C(0)N(Re), N(Re)C(0), N(Re)C(0)N(Rf), N(Re)C(0)0, OC(0)N(Re), S(0)2N(Re), or N(Re)S02, wherein Reand Rfare each independently selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(0)R9, C(0)OR9, OC(0)R9, C(0)N(R9)Rh, N(R9)C(0)Rh, S(0)yR9(where y is 0,1 or 2), S02N(R9)Rh, N(R9)S02R9, Si^XR^R1or (CH2)zNR9Rh(where z is 1 , 2 or 3); wherein R9,Rhand R' are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R9and Rhcan be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring which is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano or hydroxy;is selected from:hydrogen or methyl;a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy;W2is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)R', S02R', C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-4C)alkyl, and wherein:R6is selected from hydrogen, (1 -2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1 -2C)alkoxy, (1 -2C)haloalkyl or (1 -2C)haloalkoxy;R7is selected from hydrogen, (1 -2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1 -2C)alkoxy, (1 -2C)haloalkyl, (1 - 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(RN), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(RN), N(RN)C(0), S(0)2N(RN), or N(RN)SC>2, wherein RNis selected from hydrogen or (1 - 2C)alkyl;L2 is absent or (1 -2C)alkylene; andZ2is hydrogen, (1 -6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 - 4C)haloalkoxy, (1 -4C)alkoxy, (1 -4C)alkylamino, amino, cyano, nitro, hydroxy, C(0)R°, C(0)OR°, OC(0)R°, C(0)N(R°)RP, NR°C(0)RP, wherein R° and RPare independently selected from hydrogen or (1 -4C)alkyl; andR8is selected from (1 -2C)alkyl, -C(0)ORQ, ORQ, -C(0)NRQ, NRQRR, phenyl or a 5-membered heteroaryl, wherein RQand RRare independently selected from hydrogen or (1 -2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 -2C)haloalkoxy, (1 - 2C)alkoxy, (1 -2C)alkylamino, amino, cyano or hydroxyl; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 4 to 6 membered cydoalkyi or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, (1-4C)haloalkyl, (1-4C)hydroxyalkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl; andR3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H orCF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CFs;R10is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR 1 (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(Rs)S02, wherein Rsand R< are each independently selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is a (1-5C)alkylene optionally substituted by one or more substituents selected from (1- 2C)alkyl or oxo; andWz is halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C^R"3, COORxa, C(0)NRxaRxbor NR^R^, wherein R*3and R* areeach independently selected from hydrogen or (1-4C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc. Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), NCR^C^NCR^, N(Rw)C(0)0, OC(0)N(Rw), S(0)2N(Rw), N(Rw)S02, wherein Rwand Rxare each independently selected from hydrogen or (1- 4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1 -2C)alkyl, (1 - 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3;Xfand Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1 - 2C)haloalkyl or (1 -2C)haloalkoxy;Xh, X and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 -2C)haloalkyl or (1 -2C)haloalkoxy;with the proviso that:(i) when R3is a group of Formula B, no more than two of Xc, Xd and Xeare nitrogen; and(ii) when R3is a group of Formula C, no more than three of Xf, Xg, Xh, X and Xj are nitrogen.

[0049] In another embodiment, the present invention relates to compounds, or pharmaceutically acceptable salts, hydrates or solvates thereof, having the structural formula (I), shown below:Formula (I)wherein:Xi is selected from N or CRawherein Rais selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2- 4C)alkenyl, (2-4C)alkynyl, nitro, cyano or NRbRc, wherein Rband Rcare independently selected from hydrogen or (1-2C)alkyl;X2 is selected from N or CRd, wherein Rdis selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy;R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo;Y is absent or O, S, SO, S02, N(Re), C(O), C(0)0, OC(O), C(0)N(Re), N(Re)C(0), N(Re)C(0)N(Rf), N(Re)C(0)0, OC(0)N(Re), S(0)2N(Re), or N(Re)S02, wherein Reand Rfare each independently selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(0)R9, C(0)OR9, OC(0)R9, C(0)N(R9)Rh, N(R9)C(0)Rh, S(0)yR9(where y is 0, 1 or 2), S02N(R9)Rh, N(R9)S02R9, Si^XR^R1or (CH2)zNR9Rh(where z is 1 , 2 or 3); wherein R9,Rhand R' are each independently selectedfrom hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R9and Rhcan be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring which is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano or hydroxy;is selected from:hydrogen or methyl;a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;R7is selected from hydrogen, (1 -2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1 -2C)alkoxy, (1 -2C)haloalkyl, (1 - 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(RN), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(RN), N(RN)C(0), S(0)2N(RN), or N(RN)SC>2, wherein RNis selected from hydrogen or (1 - 2C)alkyl;l_2 is absent or (1 -2C)alkylene; andZ2is hydrogen, (1 -6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 - 4C)haloalkoxy, (1 -4C)alkoxy, (1 -4C)alkylamino, amino, cyano, nitro, hydroxy, C(0)R°, C(0)OR°, OC(0)R°, C(0)N(R°)RP, NR°C(0)RP, wherein R° and RPare independently selected from hydrogen or (1 -4C)alkyl; andR8is selected from (1 -2C)alkyl, -C(0)ORQ, ORQ, -C(0)NRQ, NRQRR, phenyl or a 5-membered heteroaryl, wherein RQand RRare independently selected from hydrogen or (1 -2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 -2C)haloalkoxy, (1 - 2C)alkoxy, (1 -2C)alkylamino, amino, cyano or hydroxyl; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1- 2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl; andR3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(Rs)S02, wherein Rsand R< are each independently selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc. Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), NKR^CCC NKR^, N(Rw)C(0)0, OC(0)N(Rw), S(0)2N(Rw), N(Rw)S02, wherein Rwand Rxare each independently selected from hydrogen or (1- 4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3;Xf and Xgare independently selected from N or CR13, whereinR13is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1- 2C)haloalkyl or (1-2C)haloalkoxy;Xh, X and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;with the proviso that:(i) when R3is a group of Formula B, only one or two of Xc, Xd and Xeare nitrogen; and(ii) when R3is a group of Formula C, no more than three of Xf, Xg, Xh, X and Xj are nitrogen.

[0050] In a particular group of compounds of the present invention, when R3is a group of Formula B, no more than one of Xc, Xd and Xeis nitrogen.

[0051] In a particular group of compounds of the present invention, when R3is a group of Formula C, no more than two of Xf, Xg, Xh, X and Xj are nitrogen.

[0052] In a particular group of compounds of the present invention, when R3is a group of Formula C, no more than one of Xf, Xg, Xh, X and Xj is nitrogen.

[0053] In a particular group of compounds of the present invention, when R1is hydrogen, R2is not hydrogen.

[0054] Particular compounds of the invention include, for example, compounds of the Formula I, or pharmaceutically acceptable salts, hydrates and / or solvates thereof, wherein, unless otherwise stated, each of Xi , X2, R\ R2, R3and any associated substituent groups has any of the meanings defined hereinbefore or in any of paragraphs (1) to (89) hereinafter: -(1) Xi is selected from N or CRa, wherein Rais selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CHF2, CF3, OCF3, acetylenyl, nitro, cyano or NRbRc, wherein Rband Rcare independently selected from hydrogen or (1- 2C)alkyl;(2) Xi is selected from N or CRa, wherein Rais selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, CF3, OCF3, acetylenyl, cyano or NH2;(3) Xi is selected from N or CRa, wherein Rais selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, acetylenyl, cyano or NH2;(4) Xi is selected from N or CRa, wherein Rais selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, acetylenyl or cyano;(5) Xi is selected from N or CRa, wherein Rais selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3 or cyano;(6) Xi is selected from N or CRa, wherein Rais selected from hydrogen, methyl, fluoro or chloro;(7) Xi is selected from N or CH;(9) X! is CH;(10) X2is selected from N, CH, CF or C-CH3;(1 1) X2 is selected from N or CH;(12) X2is N;(13) X2is selected from CH, CF or C-CH3;(14) X2is CH;(15) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo;Y is absent or O, S, SO, S02, N(Re), C(O), C(0)0, OC(O), C(0)N(Re), N(Re)C(0), S(0)2N(Re), or N(Re)S02, wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(0)R9, C(0)OR9, OC(0)R9, C(0)N(R9)Rh, N(R9)C(0)Rh, S(0)yR9(where y is 0, 1 or 2), S02N(R9)Rh, N(R9)S02R9, Si^XR^R1or (CH2)zNR9Rh(where z is 1 , 2 or 3); wherein R9,Rhand R' are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R9and Rhcan be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring which isoptionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano or hydroxy;(16) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl;Y is absent or O, S, SO, S02, N(Re), C(O), C(0)0, OC(O), C(0)N(Re), N(Re)C(0), S(0)2N(Re), or N(Re)S02, wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(0)R9, C(0)OR9, OC(0)R9, C(0)N(R9)Rh, N(R9)C(0)Rh, S(0)yR9(where y is 0, 1 or 2), S02N(R9)Rh, N(R9)S02R9, Si^XR^R1or (CH2)zNR9Rh(where z is 1 , 2 or 3); wherein R9,Rhand R' are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R9and Rhcan be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring;(17) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene;Y is absent or O, S02, N(Re), C(O), C(0)0, OC(O), C(0)N(Re), N(Re)C(0), S(0)2N(Re), or N(Re)S02, wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituentgroups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(0)R9, C(0)OR9, OC(0)R9, C(0)N(R9)Rh, N(R9)C(0)Rh, S(0)yR9(where y is 0, 1 or 2), S02N(R9)Rh, N(R9)S02R9, Si^XR^R1or (CH2)zNR9Rh(where z is 1 , 2 or 3); wherein R9,Rhand R' are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl;(18) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene;Y is absent or O, S02, C(O), C(0)0, C(0)N(Re) or S(0)2N(Re), wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(0)R9, C(0)OR9, OC(0)R9, C(0)N(R9)Rh, N(R9)C(0)Rh, S(0)yR9(where y is 0, 1 or 2), S02N(R9)Rh, N(R9)S02R9, Si^XR^R1or (CH2)zNR9Rh(where z is 1 , 2 or 3); wherein R9,Rhand R' are each independently selected from hydrogen or (1-4C)alkyl;(19) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene;Y is absent or O, S02, C(O), C(0)0, C(0)N(Re) or S(0)2N(Re), wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl,(1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rhor OR9; wherein R9,Rhand R' are each independently selected from hydrogen or (1- 4C)alkyl;(20) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene;Y is absent or O, S02, C(O), C(0)0, C(0)N(Re) or S(0)2N(Re), wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NR9Rhor OR9; wherein R9,Rhand R' are each independently selected from hydrogen or (1-4C)alkyl;(21) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-3C)alkylene;Y is absent or O, C(O), C(0)0 or C(0)N(Re), wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, (3- 6C)cycloalkyl, (3-6C)cycloalkenyl, a 5 or 6 membered heteroaryl or a 4- to 7-membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1- 2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1- 2C)aminoalkyl, cyano, hydroxy, NR9Rhor OR9; wherein R9' Rhand R' are each independently selected from hydrogen or (1-4C)alkyl;(22) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-3C)alkylene;Y is absent or O, C(O), C(0)0 or C(0)N(Re), wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, (3- 6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6 membered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1- 2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1- 2C)aminoalkyl, cyano, hydroxy, NR9Rhor OR9; wherein R9,Rhand R' are each independently selected from hydrogen or (1-4C)alkyl;(23) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-3C)alkylene;Y is absent or O, C(O), 0(0)0 or C(0)N(Re), wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6 membered heteroaryl or 4- to 7-membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy or Nhb;(24) R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-3C)alkylene;Y is absent or O, 0(0), 0(0)0 or C(0)N(Re), wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6 membered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groupsindependently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy or Nhb;(25) R1is selected from hydrogen or a group of the formula:-L-Zwherein:L is absent or (1-3C)alkylene; andZ is (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6 membered heteroaryl or 4 to 7 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NR9Rhor OR9; wherein R9and Rhare each independently selected from hydrogen or (1-2C)alkyl;(26) R1is selected from hydrogen or a group of the formula:-L-Zwherein:L is absent or (1-2C)alkylene; andZ is (1-6C)alkyl, (3-6C)cycloalkyl or 4 to 7 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NR9Rhor OR9; wherein R9and Rhare each independently selected from hydrogen or (1-2C)alkyl;(27) R1is selected from hydrogen, (1-6C)alkyl or a group of the formula:-L-Zwherein:L is (1-2C)alkylene; andZ is (3-6C)cycloalkyl or 4 to 7 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NR9RhorOR9; wherein R9and Rhare each independently selected from hydrogen or methyl;(28) R1is selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; wherein each (1- 6C)alkyl or (3-6C)cycloalkyl is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy or NH2;(29) R1is selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl;(30) R1is selected from hydrogen or (1-4C)alkyl (e.g. methyl);(31) R1is (1-4C)alkyl (e.g. methyl);(32) R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)R', SO2R1, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, whereinR1and Rmare independently selected from hydrogen or (1-4C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;l_2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, -C(0)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 4 to 6 membered cydoalkyi or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1-4C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)R', SO2R1, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R1and Rmare independently selected from hydrogen or (1-4C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, -C(0)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 4 to 6 membered cydoalkyi or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)R', SO2R1, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R1and Rmare independently selected from hydrogen or (1-4C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), C(O), C(0)0, OC(O), C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituentsselected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, -C(0)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or(iii) a group of the formula:denotes the point of attachment;ring A is a 4 to 6 membered cydoalkyi or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Racand Radare independently selected from hydrogen or methyl;R2is selected from:(i) hydrogen or methyl;(ϋ) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)alkoxy, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)R', SO2R1, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R1and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, CH2F, CF2H or CFs;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), C(O), C(0)0, OC(O), C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;l_2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, -C(0)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring; or(iii) a group of the formula:denotes the point of attachment;ring A is a 4 to 6 membered cydoalkyi or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl or halo;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from (1-2C)alkyl, fluoro, chloro, hydroxy, (1- 2C)alkoxy, CH2F, CF2H, CF3, -C(0)ORacor-NRacRad, wherein Racand Radare independently selected from hydrogen or methyl;R2is selected from:(i) hydrogen or methyl;(ϋ) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, SO2R1, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R1and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F, CF2H or CFs;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), C(O), C(0)0, OC(O), C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;l_2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, phenyl, (3- 6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)alkoxy, amino, cyano or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, -C(0)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring; or a group of the formula:wherein: denotes the point of attachment;ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from (1-2C)alkyl, fluoro, chloro, hydroxy, (1- 2C)alkoxy, CH2F, CF2H, CF3, -C(0)ORacor-NRacRad, wherein Racand Radare independently selected from hydrogen or methyl;(37) R2is selected from:(i) hydrogen or methyl;a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rn), N(Rn)C(0), S(0)2N(Rn), or N(Rn)S02, wherein Rnis selected from hydrogen or (1- 2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituentsselected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 - 4C)haloalkoxy, (1 -4C)alkoxy, (1 -4C)alkylamino, amino, cyano, nitro, hydroxy, C(0)R°, C(0)OR°, OC(0)R°, C(0)N(R°)RP, N R°C(0)RP, wherein R° and RP are independently selected from hydrogen or (1 -4C)alkyl; andR8is selected from (1 -2C)alkyl, -C(0)ORq, ORq, -C(0)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1 -2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 -2C)haloalkoxy, (1 - 2C)alkoxy, (1 -2C)alkylamino, amino, cyano or hydroxyl; or a group of the formula:wherein: denotes the point of attachment;ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1 -2C)alkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1 - 2C)alkyl, R101and R102are each independently selected from hydrogen, (1 -2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1 - 2C)alkoxy, (1 -2C)haloalkyl, (1 -2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Racand Radare independently selected from hydrogen or (1 -2C)alkyl;(38) R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rn), N(Rn)C(0), S(0)2N(Rn), or N(Rn)S02, wherein Rnis selected from hydrogen or (1-2C)alkyl;l_2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocyclic ring or a 4-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1- 2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, and wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;(39) R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rn), N(Rn)C(0), S(0)2N(Rn), or N(Rn)S02, wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocydic ring or a 4-6-membered heterocyclic ring; ora group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1- 2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, and wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;(40) R2is selected from:(i) hydrogen or methyl;a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, CH2F, CF2H or CFs;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), C(O), C(0)0, OC(O), C(0)N(Rn), N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocydic ring or a 4-6-membered heterocyclic ring; ora group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(0)ORacor-NRacRad, and wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;(41) R2is selected from:(i) hydrogen or methyl;a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H, CF3 or amino; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), C(O), C(0)0, OC(O), C(0)N(Rn), N(Rn)C(0), wherein Rnis selected from hydrogen or (1- 2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3- 6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocyclic ring or a 4-6- membered heterocyclic ring; or(iii) a group of the formula:wherein: denotes the point of attachment;R100is selected from hydrogen, (1-2C)alkyl, -C(0)-CH3or -C(0)OR:wherein Rabis (1-2C)alkyl;(42) R2is selected from:hydrogen or methyl;a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H, CF3 or amino; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R1and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), C(O), C(0)0, OC(O), C(0)N(Rn), N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocyclic ring or a 4-6-membered heterocyclic ring; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;R101and R102are each independently selected from hydrogen, (1- 2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;(43) R2is selected from:hydrogen or methyl;a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H, CF3 or amino; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), C(O), C(0)0, OC(O), C(0)N(Rn), N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;l_2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocydic ring or a 4-6-membered heterocyclic ring; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;R101is selected from hydrogen or methyl; andR102is selected from (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;(44) R2is selected from:hydrogen or methyl;a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H or amino; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from methyl, fluoro, chloro, OCH3, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, C(O), C(0)0, OC(O), C(0)N(Rn) or N(Rn)C(0, wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(0)ORacor-NRacRad, and wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H or amino; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from methyl, fluoro, chloro, OCH3, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, C(O), C(0)0, OC(O), C(0)N(Rn) or N(Rn)C(0, wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1 -2C)haloalkoxy, (1 -2C)alkoxy, (1 - 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1 -2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1 -2C)alkyl; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1 -2C)alkyl or -C(0)ORabwherein Rabis (1 -2C)alkyl, R101and R102are each independently selected from hydrogen, (1 -2C)alkyl, fluoro, chloro, hydroxy, (1 -2C)alkoxy, CH2F, CF2H, CF3, -C(0)ORacor-NRacRad, and wherein Racand Radare independently selected from hydrogen or (1 -2C)alkyl;R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CHR4or C(O), wherein R4is selected from hydrogen, (1 -2C)alkyl, fluoro, hydroxy, cyano, nitro, (1 -2C)alkoxy, (1 -2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1-2C)alkyl;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F, CF2H or CFs;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), S02, C(O), C(0)0, OC(O), C(0)N(Rn), N(Rn)C(0), S(0)2N(Rn), or N(Rn)S02, wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl; orR6and R7can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(0)ORacor-NRacRad, and wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CHR4or C(O), wherein R4is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H, CFs or amino;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F, CF2H or CF3;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(Rn), S02, C(O), C(0)0, OC(O), C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl; orR6and R7can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(0)ORacor-NRacRad, and wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;(48) R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CHR4or C(O), wherein R4is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H, CFs or amino;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F, CF2H or CF3;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, C(0)0, C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl; orR6and R7can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro or hydroxy; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl or -C(0)ORabwherein Rabis (1-2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, hydroxy, (1-2C)alkoxy or -C(0)ORac, and wherein Racis selected from hydrogen or (1-2C)alkyl;R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CHR4or C(O), wherein R4is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H or amino;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, C(0)0, C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl; orR6and R7can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl or -C(0)ORabwherein Rabis (1-2C)alkyl, R101is selected from hydrogen or methyl and R102is selected from (1-2C)alkyl, hydroxy, (1-2C)alkoxy, C(0)ORacor -NRacRad, and wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl;R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein: denotes the point of attachment;Wi is selected from CHR4or C(O), wherein R4is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano or (1-2C)alkoxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, C(0)0, C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3- 6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or pyrazolyl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl; or(iii) a group of the formula:wherein: denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl or -C(0)ORabwherein Rabis (1-2C)alkyl, R101is selected from hydrogen or methyl and R102is selected from (1-2C)alkyl,hydroxy or C(0)ORacwherein Racis selected from hydrogen or (1 - 2C)alkyl;(51 ) R2is selected from a group of the formula:wherein: denotes the point of attachment;Wi is selected from CHR4, wherein R4is selected from hydrogen, (1 -2C)alkyl, fluoro, hydroxy, cyano or (1 -2C)alkoxy;W2is CR6R7R8, wherein:R6is selected from hydrogen, (1 -2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1 -2C)alkoxy;R7is selected from hydrogen, (1 -2C)alkyl, fluoro, chloro, hydroxy, cyano, (1 -2C)alkoxy, (1 -2C)haloalkyl, (1 -2C)haloalkoxy; andR8is selected from (1 -2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or pyrazolyl, wherein Rqand Rrare independently selected from hydrogen or (1 -2C)alkyl;(52) R2is selected from a group of the formula:wherein: denotes the point of attachment;W2is CR6R7R8, wherein:R6is selected from (1 -2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1 -2C)alkoxy; andR7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy;(53) R2is a group of the formula:wherein: denotes the point of attachment;(54) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:-Y3-Z3wherein:Y3is absent or O, N(RS)(CRSR 1 (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), S(0)2N(Rs) or N(Rs)S02, wherein Rsis selected from hydrogen or (1- 4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1 -5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; andWz is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa, COOR"3, C(0)NRxaRxbor NRxaRxb, wherein R*3and Rxbare each independently selected from hydrogen or (1-4C)alkyl; and wherein each aryl, 5- or6-membered heteroaryl or 4- to 7- membered heterocyclyl is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, amino, cyano or hydroxy; a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), S(0)2N(Rw) or N(RW)SC>2, wherein Rwis selected from hydrogen or (1-4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl;iii) a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H orCF3;Xf and Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, (1- 2C)alkyl, (1-2C)haloalkyl or (1-2C)haloalkoxy;Xh, X and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;(55) R3is selected from: i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), S(0)2N(Rs) or N(Rs)S02, wherein Rsis selected from hydrogen or (1- 4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1 -3C)alkylene optionally substituted by one or more (1-2C)alkyl groups; andWz is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa, COOR"3, C(0)NRxaRxbor NRxaRxb, wherein R*3and Rxbare each independently selected from hydrogen or (1-4C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), S(0)2N(Rw) or N(RW)SC>2, wherein Rwis selected from hydrogen or (1 -4C)alkyl; andZ5 is hydrogen, (1 -6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, (1 - 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1 - 4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1 -2C)alkyl, (1 -2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3;Xfand Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, (1 - 2C)alkyl, (1 -2C)haloalkyl or (1 -2C)haloalkoxy;Xh, X and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;(56) R3is selected from: i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR 1 (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), S(0)2N(Rs) or N(Rs)S02, wherein Rsis selected from hydrogen or (1- 4C)alkyl; andZ3 is hydrogen, (1 -6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 1 1 - membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1 - 4C)alkyl, (3-6C)cycloalkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1 -4C)alkyl or (3-6C)cycloalkyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is a (1 -5C)alkylene optionally substituted by one or more substituents selected from (1 -2C)alkyl or oxo; andWz is halo, (1 -4C)haloalkyl, (1 - 4C)haloalkoxy, cyano, hydroxy, (1 - 4C)alkoxy, 0(0)^, COORxa, C(0)NRxaRxbor NRxaRxb, wherein R"3and R* are each independently selected from hydrogen or (1 -4C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), S(0)2N(Rw) or N(RW)S02, wherein Rwis selected from hydrogen or (1-4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1-2C)alkyl,(1-2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3;Xf and Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, (1- 2C)alkyl, (1-2C)haloalkyl or (1-2C)haloalkoxy;Xh, X and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;(57) R3is selected from: i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or N(RS)(CRSR (where qi is 0, 1 or 2), S, C(O), C(0)0, C(0)N(Rs), N(Rs)C(0), S(0)2N(Rs) or N(Rs)S02, wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 1 1-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1-3C)alkylene; andWz is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa, COOR"3, C(0)NRxaRxbor NRxaRxb, wherein R*3and Rxbare each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1-4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3;Xfand Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, methyl, CH2F,Xh, Xi and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;(58) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1 - 2C)alkyl, (1 -2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1 - 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or N(RS)(CRSR (where qi is 0, 1 or 2), S, C(O), C(0)0, C(0)N(Rs), N(Rs)C(0), S(0)2N(Rs) or N(Rs)S02, wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 1 1-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1 - 4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is a (1-3C)alkylene; andWz is halo, (1-4C)haloalkyl, (1 - 4C)haloalkoxy, cyano, hydroxy, (1 - 4C)alkoxy, 0(0)^, COORxa, C(0)NRxaRxbor NRxaRxb, wherein R"3andare each independently selected from hydrogen or (1-4C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1-4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3;Xfand Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, methyl, CH2F,Xh, Xi and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;(59) R3is selected fromi) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(Rs)S02, wherein Rsand R' are each independently selected from hydrogen or (1-4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl;a group of Formula B shown below:Formula Bwherein:denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), NiR^CiOJNiR3"), N(Rw)C(0)0, OC(0)N(Rw), S(0)2N(Rw), N(Rw)S02, wherein Rwand Rxare each independently selected from hydrogen or (1- 4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3;Xf and Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1- 2C)haloalkyl or (1-2C)haloalkoxy;Xh, X and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;(60) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), S(0)2N(RS), N(RS)S02, wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyi, mercapto, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN orR11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), S(0)2N(Rw), N(Rw)S02, wherein Rwis selected from hydrogen or (1-4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 isoptionally further substituted by one or more substituent groups independently selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1 -4C)alkyl or (3-6C)cycloalkyl; andiii) a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1 -2C)alkyl, (1 -2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3;Xfand Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, (1 -2C)alkyl, (1 -2C)haloalkyl or (1 -2C)haloalkoxy;Xh, Xi and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 - 2C)haloalkyl or (1 -2C)haloalkoxy;is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro, acetylenyl, CH2F or CF2H;R10is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), S(0)2N(RS), N(RS)SC>2, wherein Rsis selected from hydrogen or (1 -4C)alkyl; andZ3is hydrogen, (1 -6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or (1 -4C)alkyl;ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc. Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCHs;R11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), S(0)2N(Rw), N(Rw)S02, wherein Rwis selected from hydrogen or (1-4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen or (1-4C)alkyl; andiii) a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;Xf and Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1-2C)haloalkyl or (1-2C)haloalkoxy;Xh, X and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl or (1-2C)haloalkoxy;(62) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano, acetylenyl, CH2F, CF2H or CF3;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro or acetylenyl;R10is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, C(0)N(Rs) or S(0)2N(Rs), wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or moresubstituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or (1-2C)alkyl;ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc. Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCHs;R11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1- 4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen or (1-2C)alkyl; andiii) a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, acetylenyl, CH2F, CF2H or CF3;Xf and Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, methyl, CH2F, CF2H or CFs;R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl or (1-2C)haloalkoxy;(63) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano, acetylenyl, CH2F, CF2H or CF3;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro or acetylenyl;R10is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, C(0)N(Rs) or S(0)2N(Rs), wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or (1-2C)alkyl;ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc. Xd and Xeare independently selected from N, CH, CF, CCI, C-CN orR11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) orS(0)2N(Rw), wherein Rwis selected from hydrogen or (1- 4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen or (1-2C)alkyl; andiii) a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, acetylenyl, CH2F, CF2H or CF3;Xf and Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro or methyl;R14is selected from hydrogen, halo, methyl, OCH3, CH2F, CF2H or CF3;(64) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are both CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R10is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, C(0)N(Rs) or S(0)2N(Rs), wherein Rsis selected from hydrogen or (1 -4C)alkyl; andZ3is hydrogen, (1 -6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 -2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or (1 -2C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xcand Xd are independently selected from N, CH, CF, CCI, C-CN or CCHs;R11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1- 4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen or (1-2C)alkyl; andiii) a group of Formula C shown below:Formula Cwherein:^'denotes the point of attachment;R12is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;Xfand Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro or methyl;R14is selected from hydrogen, halo, methyl, OCH3, CH2F, CF2H or CF3;(65) s selected from:) a group of Formula A shown below:Formula Awherein:-^denotes the point of attachment;Xbis CRx1, wherein Rx1is selected from hydrogen or chloro;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R10is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, cyano, or a group of the formula:-Y3-Z3wherein:Y3is absent or C(O), C(0)0, C(0)N(Rs) or S(0)2N(Rs), wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (2-4C)alkynyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or (1-2C)alkyl;ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc is selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1- 4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz,ORy, wherein Ryand Rzare each independently selected from hydrogen or (1 -2C)alkyl; andiii) a group of Formula C shown below:Formula Cwherein: denotes the point of attachment;R12is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;Xfand Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro or methyl;R14is selected from hydrogen, halo, methyl, OCH3, CH2F, CF2H or CF3;(66) R3is selected from: i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro,bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(RS)S02, wherein Rsand R' are each independently selected from hydrogen or (1- 4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1 -5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; andWz is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa, COOR"3, C(0)NRxaRxbor NRxaRxb, wherein R*3and Rxbare each independently selected from hydrogen or (1-4C)alkyl; and wherein each aryl, 5- or 6-membered heteroaryl or 4- to 7- membered heterocyclyl is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, amino, cyano or hydroxy; a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:-Y5-Z5wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), N(Rw)C(0)N(Rx), N(Rw)C(0)0, OC(0)N(Rw), S(0)2N(Rw), N(Rw)S02, wherein Rwand Rxare each independently selected from hydrogen or (1 - 4C)alkyl; andZ5 is hydrogen, (1 -6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, (1 - 4C)haloalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1 - 4C)alkyl or (3-6C)cycloalkyl;(67) R3is selected from i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1 -2C)alkyl, (1 -2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR 1 (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(RS)S02, wherein Rsand R' are each independently selected from hydrogen or (1- 4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1 -5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; andWz is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa, COOR"3, C(0)NRxaRxbor NRxaRxb, wherein R*3and Rxbare each independently selected from hydrogen or (1-4C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), NKR^CCC NKR^, N(Rw)C(0)0, OC(0)N(Rw), S(0)2N(Rw), N(Rw)S02, wherein Rwand Rxare eachindependently selected from hydrogen or (1- 4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)haloalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl;(68) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:-Y3-Z3wherein:Y3is absent or O, N(RS)(CRSR 1 (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(RS)S02, wherein Rsand R' are each independently selected from hydrogen or (1 - 4C)alkyl; andZ3is hydrogen, (1 -6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 1 1 - membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1 - 4C)alkyl, (3-6C)cycloalkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1 -4C)alkyl or (3-6C)cycloalkyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is a (1 -5C)alkylene optionally substituted by one or more substituents selected from (1 -2C)alkyl or oxo; andWz is halo, (1 -4C)haloalkyl, (1 - 4C)haloalkoxy, cyano, hydroxy, (1 - 4C)alkoxy, 0(0)^, COORxa, C(0)NRxaRxbor NRxaRxb, wherein R"3and R* are each independently selected from hydrogen or (1 -4C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), NKR^CCC NKR^, N(Rw)C(0)0, OC(0)N(Rw), S(0)2N(Rw), N(Rw)S02, wherein Rwand Rxare each independently selected from hydrogen or (1- 4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;(69) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F,R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or N(RS)(CRSR (where qi is 0, 1 or 2), S, C(O), C(0)0, C(0)N(Rs), N(Rs)C(0) or S(0)2N(RS), wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1-3C)alkylene; andWz is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa, COOR"3, C(0)NRxaRxbor NRxaRxb, wherein R*3and Rxbare each independently selected from hydrogen or (1-4C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano,nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1 -4C)alkyl; andZ5 is hydrogen, (1 -6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, (1 - 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1 - 4C)alkyl or cyclopropyl;(70) R3is selected from i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1 -2C)alkyl, (1 -2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or N(RS)(CRSR (where qi is 0, 1 or 2), S, C(O), C(0)0, C(0)N(Rs), N(Rs)C(0) or S(0)2N(RS), wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; andWz is halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, 0(0)^, COORxa, C(0)NRxaRxbor NRxaRxb, wherein R"3and R* are each independently selected from hydrogen or (1 -4C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R1 1is selected from hydrogen, halo, (1 -4C)alkyl, (1 - 4C)alkoxy, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1 -4C)alkyl; andZ5 is hydrogen, (1 -6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1 -4C)alkyl or cyclopropyl;rom i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R10is selected from hydrogen, halo, (1-4C)alkyl, (1 - 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3 is absent or N(Rs)(CH2)qi (where qi is 0, 1 or 2), S, C(O), C(0)0, C(0)N(Rs), or S(0)2N(Rs), wherein Rsis selected from hydrogen or (1 - 4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 1 1 - membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituentgroups independently selected from oxo, (1 - 4C)alkyl, (3-6C)cycloalkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1 -4C)alkyl or cyclopropyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is a (1 -3C)alkylene; andWz is halo, (1 -2C)haloalkyl, (1 - 2C)haloalkoxy, cyano, hydroxy, (1 - 2C)alkoxy, 0(0)^, COORxa, C(0)NRxaRxbor NRxaRxb, wherein R"3and R* are each independently selected from hydrogen or (1 -2C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xcand Xd are independently selected from N, CH, CF, CCI or CCH3;R1 1is selected from hydrogen, halo, (1 -4C)alkyl, (1 - 4C)alkoxy, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0,C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1 -2C)alkyl; andZ5 is hydrogen, (1 -6C)alkyl, aryl, (3- 8C)cycloalkyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 - 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen or (1 - 2C)alkyl;(72) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein R:selected from hydrogen, fluoro, chloro, bromo, (1 -2C)alkyl, 2C)alkoxy, cyano, nitro, acetylenyl, CH2F or CF2H;R9is selected from fluoro, chloro, bromo, (1 -2C)alkyl, (1 -2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:-Y3-Z3wherein:Y3is absent or C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), S(0)2N(RS), N(RS)SC>2, wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyi, mercapto, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc. Xd and Xeare independently selected from N, CH, CF, CCI, C-CN orR11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, OC(O), C(0)N(Rw), N(Rw)C(0), S(0)2N(Rw), N(Rw)S02, wherein Rwis selected from hydrogen or (1-4C)alkyl; andZ5is hydrogen, (1 -6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1 -4C)alkyl or (3-6C)cycloalkyl;(73) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro or acetylenyl;R10is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, C(0)N(Rs) or S(0)2N(Rs), wherein Rsis selected from hydrogen or (1 -4C)alkyl; andZ3is hydrogen, (1 -6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6-membered heteroaryl or 5- or 6-membered heterocyclyl;wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or (1-2C)alkyl;ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xcand Xd are independently selected from N, CH, CF, CCI or CCH3;R11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1- 4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen or (1-2C)alkyl;(74) R3is selected from:a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are both CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo or methyl;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R10is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, C(0)N(Rs) or S(0)2N(Rs), wherein Rsis selected from hydrogen or (1 -4C)alkyl; andZ3is hydrogen, (1 -6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 -2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or (1 -2C)alkyl;a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xcand Xd are independently selected from N, CH, CF, CCI or CCH3;R1 1is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1 - 4C)alkyl; andZ5is hydrogen, (1 -6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 - 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen or (1 -2C)alkyl;(75) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xb is CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo or methyl;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R10is selected from hydrogen, halo, (1 -2C)alkyl, (1 -2C)alkoxy, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or C(O), C(0)0, C(0)N(Rs) or S(0)2N(Rs), wherein Rsis selected from hydrogen or (1 -4C)alkyl; andZ3is hydrogen, (1 -6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 -2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or (1 -2C)alkyl;ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc is selected from N, CH, CF, CCI or CCH3;R11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1- 4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen or (1-2C)alkyl;(76) R3is selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xb is CRx1, wherein Rx1is selected from hydrogen or chloro;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R10is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:-Y3-Z3wherein:Y3is absent or C(O), C(0)0, C(0)N(Rs) or S(0)2N(Rs), wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (2-4C)alkynyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or (1-2C)alkyl;ii) a group of Formula B shown below:Formula Bwherein: denotes the point of attachment;Xc is selected from N, CH, CF, CCI or CCH3;R11is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1- 4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz,ORy, wherein Ryand Rzare each independently selected from hydrogen or (1-2C)alkyl;(77) R3is a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(RS)S02, wherein Rsand R' are each independently selected from hydrogen or (1- 4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1 -5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; andWz is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa, COOR"3, C(0)NRxaRxbor NRxaRxb, wherein R*3and Rxbare each independently selected from hydrogen or (1-4C)alkyl; and wherein each aryl, 5- or 6-membered heteroaryl or 4- to 7- membered heterocyclyl is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, amino, cyano or hydroxy;(78) R3is a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(RS)S02, wherein Rsand R' are each independently selected from hydrogen or (1- 4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituentgroups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1 -5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; andWz is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa,COOR"3, C(0)NRxaRxbor NRxaR wherein and jxb are each independently selected from hydrogen or (1-4C)alkyl;(79) R3is a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro,bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(RS)S02, wherein Rsand R' are each independently selected from hydrogen or (1- 4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; andWz is halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, cyano, hydroxy, (1- 4C)alkoxy, 0(0)^, COORxa, C(0)NRxaRxbor NRxaRxb, wherein R"3and R* are each independently selected from hydrogen or (1-4C)alkyl;(80) R3is a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R9is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3 is absent or N(Rs)(CH2)qi (where qi is 0, 1 or 2), S, C(O), C(0)0, C(0)N(Rs), N(Rs)C(0), or S(0)2N(RS), , wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3 is hydrogen, (1 -6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 1 1 -membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1 -4C)alkyl, (3-6C)cycloalkyl, halo, (1 - 4C)haloalkyl, (1 -4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1 -4C)alkyl or cyclopropyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is a (1 -3C)alkylene; andWz is halo, (1 -2C)haloalkyl, (1 - 2C)haloalkoxy, cyano, hydroxy, (1 - 2C)alkoxy, 0(0)^, COORxa, C(0)NRxaRxbor NRxaRxb, wherein R"3and R* are each independently selected from hydrogen or (1 -2C)alkyl;Formula Awherein: denotes the point of attachment;Xais CH or N;Xbis selected from CH, CCI, CF, CBr or CCH3;R9is selected from chloro or cyano;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3 is absent or N(Rs)(CH2)qi (where qi is 0, 1 or 2), S, C(O), C(0)0, C(0)N(Rs), N(Rs)C(0), or S(0)2N(RS), , wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 1 1-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or cyclopropyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1-3C)alkylene; andWz is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, cyano, hydroxy, (1-2C)alkoxy, C(0)Rxa, COOR"3, C(0)NRxaRxbor NRxaRxb, wherein R*3and Rxbare eachindependently selected from hydrogen or(1 -2C)alkyl;(82) R3is a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xais CH or N;Xb is selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R9is selected from chloro or cyano;R10is selected from hydrogen, halo, (1-4C)alkyl, (1 - 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano or a group of the formula:wherein:Y3 is absent or N(Rs)(CH2)qi (where qi is 0 or 1), C(O), C(0)0 or C(0)N(Rs), wherein Rsis selected from hydrogen or methyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, 5- or 6-membered heteroaryl or 4 to 9-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-3C)alkyl, cyclopropyl, halo, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(0)NRuRv, NRURVorORu, wherein Ruand Rvare each independently selected from hydrogen or methyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is a (1 -3C)alkylene; andWz is halo, (1 -2C)haloalkyl, (1 - 2C)haloalkoxy, cyano, hydroxy, (1 - 2C)alkoxy, 0(0)^, COORxa, C(0)NRxaRxbor NRxaRxb, wherein R"3and R* are each independently selected from hydrogen or methyl;(83) R3is a group of Formula A shownFormula Awherein: denotes the point of attachment;Xais CH or N;Xb is selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R9is selected from chloro or cyano;R10is selected from hydrogen, halo, (1 -4C)alkyl, (1 - 4C)alkoxy, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, cyano or a group of the formula:wherein:Y3 is absent or N(Rs)(CH2)qi (where qi is 0 or 1),C(O), C(0)0 or C(0)N(Rs), wherein Rsis selected from hydrogen or methyl; andZ3is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, 5- or 6-membered heteroaryl or 4 to 9-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-3C)alkyl, cyclopropyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or methyl;(84) R3is a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xais CH or N;Xb is selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R9is selected from chloro or cyano;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy or a group of the formula:wherein:Y3 is absent or C(0)N(Rs), wherein Rsis selected from hydrogen or methyl; andZ3 is (3-6C)cycloalkyl, 5- or 6-membered heteroaryl or 4 to 9-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, cyano, hydroxy, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or methyl;(85) R3is a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xais CH or N;Xbis selected from CH, CCI, CF, CBr or CCH3;R9is selected from chloro or cyano;R10is selected from a (3-6C)cycloalkyl, a 5- or 6- membered heteroaryl or a 4 to 9-membered heterocyclyl; wherein said (3-6C)cycloalkyl, 5- or 6- membered heteroaryl or 4 to 9-membered heterocyclyl is optionally further substituted by one or more substituent groups independently selected from (1- 2C)alkyl, halo, (1-2C)haloalkyl, cyano, hydroxy, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or methyl;(86) R3is a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xais CH or N;Xbis selected from CH, CCI, CF, CBr or CCH3;R9is selected from chloro or cyano;R10is selected from a 5- or 6-membered heteroaryl or a 4 to 8-membered heterocyclyl; wherein said 5- or 6- membered heteroaryl or 4 to 8-membered heterocyclyl is optionally further substituted by one or more substituent groups independently (1-4C)alkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano or hydroxy;(87) R3is a compound of Formula A as defined in any one of paragraphs 54 to 86 above;(88) R3is a compound of Formula B as defined in any one of paragraphs 54 to 76 above;(89) R3is a compound of Formula C as defined in any one of paragraphs 54 to 65 above.

[0055] Suitably, a heteroaryl is a 5- or 6-membered heteroaryl ring comprising one, two or three heteroatoms selected from N, O or S.

[0056] Suitably, a heterocyclyl group is a 4-, 5- or 6-membered heterocyclyl ring comprising one, two or three heteroatoms selected from N, O or S. Most suitably, a heterocyclyl group is a 5-, 6- or 7-membered ring comprising one, two or three heteroatoms selected from N, O or S [e.g. morpholinyl (e.g. 4-morpholinyl), pyridinyl, piperazinyl, homopiperazinyl or pyrrolidinonyl].

[0057] Suitably an aryl group is phenyl.

[0058] Suitably, Xi is as defined in any one of paragraphs (1) to 9) above. Most suitably, Xi is as defined in paragraph (9) above.

[0059] Suitably, X2 is as defined in any one of paragraphs (10) to (14) above. Most suitably, X2 IS as defined in paragraph (14) above.

[0060] Suitably, R1is as defined in any one of paragraphs (15) to (31) above. Most suitably, R1is as defined in paragraph (31) above.

[0061] Suitably, R2is as defined in any one of paragraphs (32) to (53) above. Most suitably, R2is as defined in any one of paragraphs (49) or (53) above.

[0062] Most suitably, R3is as defined in any one of paragraphs (54) to (86) above. Most suitably R3is as defined in paragraph (86) above.

[0063] In a particular group of compounds of the invention, X2 is CH, i.e. the compounds have the structural formula la (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof:Formula lawherein each of Xi , R1, R2and R3are as defined hereinabove.

[0064] In an embodiment of the compounds of Formula la:Xi is as defined in any one of paragraphs (1) to (9) above;R1is as defined in any one of paragraphs (15) to (31) above;R2is as defined in any one of paragraphs (32) to (53) above; andR3is as defined in any one of paragraphs (54) to (86) above.

[0065] In another embodiment of the compounds of Formula la:Xi is as defined in paragraph (9) above;R1is as defined in any one of paragraphs (28) to (31) above;R2is as defined in any one of paragraphs (49) to (53) above; andR3is as defined in paragraph (86) above.

[0066] In a particular group of compounds of the invention, Xi and X2 are CH, i.e. the compounds have the structural formula lb (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof:Formula lbwherein each of R1, R2and R3are as defined hereinabove.

[0067] In an embodiment of the compounds of Formula lb:R1is as defined in any one of paragraphs (15) to (31) above;R2is as defined in any one of paragraphs (32) to (53) above; andR3is as defined in any one of paragraphs (54) to (86) above.

[0068] In another embodiment of the compounds of Formula lb:R1is as defined in any one of paragraphs (28) to (31) above;R2is as defined in any one of paragraphs (49) to (53) above; andR3is as defined in paragraph (86) above.

[0069] In a particular group of compounds of the invention, R2is of the formula shown below, i.e. the compounds have the structural formula Ic (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof:Formula Icwherein each of Xi , X2, R\ R3, W1and W2are as defined hereinabove.

[0070] In an embodiment of the compounds of Formula Ic:Xi is as defined in any one of paragraphs (1) to (9) above;X2 is as defined in any one of paragraphs (10) to (14) above;R1is as defined in any one of paragraphs (15) to (31) above;W1and W2are as defined in any one of paragraphs (32) to (51) above; andR3is as defined in any one of paragraphs (54) to (86) above.

[0071] In another embodiment of the compounds of Formula lc:Xi is as defined in paragraph (9) above;X2 is as defined in paragraph (14) above;R1is as defined in any one of paragraphs (28) to (31) above;W1and W2are as defined in paragraph (51) above; andR3is as defined in paragraph (86) above.

[0072] In a particular group of compounds of the invention, Xi and X2 are CH and R2is of the formula shown below, i.e. the compounds have the structural formula Id (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof:Formula Idwherein each of R1, R3, W1and W2are as defined hereinabove

[0073] In an embodiment of the compounds of Formula Id:R1is as defined in any one of paragraphs (15) to (31) above;W1and W2are as defined in any one of paragraphs (32) to (51) above; andR3is as defined in any one of paragraphs (54) to (86) above.

[0074] In another embodiment of the compounds of Formula Id:R1is as defined in any one of paragraphs (28) to (31) above;W1and W2are as defined in paragraph (51) above; andR3is as defined in paragraph (86) above.

[0075] In a particular group of compounds of the invention, Xi and X2 are CH, R1is methyl and R2is of the formula shown below, i.e. the compounds have the structural formula le (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof:Formula lewherein each of R3, W1and W2are as defined hereinabove.

[0076] In an embodiment of the compounds of Formula le:W1and W2are as defined in any one of paragraphs (32) to (51) above; andR3is as defined in any one of paragraphs (54) to (86) above.

[0077] In another embodiment of the compounds of Formula le:W1and W2are as defined in paragraph (51) above; andR3is as defined in paragraph (86) above.

[0078] In a particular group of compounds of the invention, Xi and X2 are CH and R2is of the formula shown below, i.e. the compounds have the structural formula If (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof:Formula Ifwherein each of R1, R3and R100are as defined hereinabove.

[0079] In an embodiment of the compounds of Formula If:R1is as defined in any one of paragraphs (15) to (31) above;R3is as defined in any one of paragraphs (54) to (86) above; andR100is as defined in any one of paragraphs (39) to (41), or (45) to (50) above.

[0080] In another embodiment of the compounds of Formula If:R1is as defined in any one of paragraphs (28) to (31) above;R3is as defined in paragraph (86) above; andR100is -C(0)ORabwherein Rabis selected from (1-2C)alkyl.

[0081] In a particular group of compounds of the invention, Xi and X2 are CH and R2is of the formula shown below, i.e. the compounds have the structural formula Ig (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof:Formula Igwherein each of R1, R3, R101, R102and ring A are as defined hereinabove.

[0082] In an embodiment of the compounds of Formula Ig:R1is as defined in any one of paragraphs (15) to (31) above;R3is as defined in any one of paragraphs (54) to (86) above; andR101, R102and ring A are as defined in any one of paragraphs (39) to (41), or (43) to(50) above.

[0083] In another embodiment of the compounds of Formula Ig:R1is as defined in any one of paragraphs (28) to (31) above;R3is as defined in paragraph (86) above; andR101, R102and ring A are as defined in paragraphs (49) or (50) above.

[0084] In a particular group of compounds of the invention, the compounds have the structural formula Ih (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof:Formula Ihwherein each of Xi , X2, Xa, Xb, R\ R2R9and R10are as defined hereinabove.

[0085] In an embodiment of the compounds of Formula Ih:Xi is as defined in any one of paragraphs (1) to (9) above;X2 is as defined in any one of paragraphs (10) to (14) above;Xaand Xb are as defined in any one of paragraphs (54) to (86) above;R1is as defined in any one of paragraphs (15) to (31) above;R2is as defined in any one of paragraphs (32) to (53) above;R9is as defined in any one of paragraphs (54) to (86) above; andR10is as defined in any one of paragraphs (54) to (86) above.

[0086] In another embodiment of the compounds of Formula Ih:Xi is as defined in paragraph (9) above;X2 is as defined in paragraph (14) above;Xaand Xb are as defined in paragraph (83) above;R1is as defined in any one of paragraphs (28) to (31) above;R2is as defined in any one of paragraphs (51) to (53) above;R9is as defined in paragraph (86) above; andR10is as defined in paragraph (86) above.

[0087] In a particular group of compounds of the invention, the compounds have the structural formula Ij (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof:Formula Ijwherein each of Xi , X2, Xa, Xb, R\ R6R7, R8, R9and R10are as defined hereinabove.

[0088] In an embodiment of the compounds of Formula Ij:Xi is as defined in any one of paragraphs (1) to (9) above;X2 is as defined in any one of paragraphs (10) to (14) above;Xaand Xb are as defined in any one of paragraphs (54) to (86) above;R1is as defined in any one of paragraphs (15) to (31) above;R6, R7and R8are each as defined in any one of paragraphs (50) to (51) above;R9is as defined in any one of paragraphs (54) to (86) above; andR10is as defined in any one of paragraphs (54) to (86) above.

[0089] In another embodiment of the compounds of Formula Ij:Xi is as defined in paragraph (9) above;X2 is as defined in paragraph (14) above;Xaand Xb are as defined in paragraph (86) above;R1is as defined in any one of paragraphs (28) to (31) above;R6is OH;R7and R8are CH3;R9is as defined in paragraph (86) above; andR10is as defined in paragraph (86) above.

[0090] Particular compounds of the present invention include any of the compounds exemplified in the present application, or a pharmaceutically acceptable salt or solvate thereof, and, in particular, any of the following:6-Chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]- / V-methyl-pyridine-2-carboxamide;2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]- 6-methyl-pyridine-3-carbonitrile;6-chloro-5-cyano-4-[(1 ,3-dimethyl-2-oxo-benzimidazol-5-yl)amino]pyridine-2- carboxylic acid;6-chloro-5-cyano- / V-methyl-4-[[1-methyl-2-oxo-3-[(3S)-3-pyrazol-1- ylbutyl]benzimidazol-5-yl]amino]pyridine-2-carboxamide;6-chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylic acid;6-chloro-5-cyano- / V-methyl-4-[(1-methyl-2-oxo-3 / - / -benzimidazol-5- yl)amino]pyridine-2-carboxamide;6-chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-2-oxo-1-(tetrahydropyran-4- ylmethyl)benzimidazol-5-yl]amino]- / \ / -methyl-pyridine-2-carboxamide;Ethyl 7-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3- methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-butanoate;2-bromo-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;2-chloro-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]-6- methyl-pyridine-3-carbonitrile;5-[(2,5-dichloro-4-pyridyl)amino]-3-[(3f?)-3-hydroxybutyl]-1-methyl-benzimidazol-2- one;5-[(2,5-dichloropyrimidin-4-yl)amino]-3-(3-hydroxy-3-methyl-butyl)-1-methyl- benzimidazol-2-one;Ethyl 7-[[3-[(3 )-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;4- chloro-6-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrimidine-5-carbonitrile;5- [(2,3-dichloro-4-pyridyl)amino]-3-[(3f?)-3-hydroxybutyl]-1-methyl-benzimidazol-2- one;Ethyl 3-fluoro-7-((3-(2-hydroxybutyl)-1-methyl-2-oxo-2,3-dihydro-1 / - / - benzo[d]imidazol-5-yl)amino)pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;Methyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Ethyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Isopropyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Ethyl 6-chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylate;6- Chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylic acid;Methyl 3-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-propanoate;Methyl 4-[6-[(5-chloro-2-methyl-pyrimidin-4-yl)amino]-3-methyl-2-oxo-benzimidazol- 1 -yl]-2-methyl-butanoate;6-Chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]-N-methyl-pyridine-2-carboxamide;Methyl 4-[6-[[2-chloro-3-cyano-6-(3-methyl-1 ,2,4-oxadiazol-5-yl)-4-pyridyl]amino]-3- methyl-2-oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl (2S)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate;Methyl 4-[6-[[2-chloro-3-cyano-6-(methylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl 4-[6-[[6-(but-3-ynylcarbamoyl)-2-chloro-3-cyano-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl 4-[6-[[2-chloro-3-cyano-6-(dimethylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;6-Chloro-5-cyano-N-[2-(dimethylamino)ethyl]-4-[(1 ,3-dimethyl-2-oxo-benzirnidazol- 5-yl)amino]pyridine-2-carboxamide;Ethyl 7-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-hydroxy-butanoate;2-Chloro-4-[[3-(2,3-dihydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methoxy-butanoate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-ethoxy-butanoate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]butanoate;methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-(cyclopropylmethoxy)butanoate;2-chloro-4-[[3-(2-hydroxy-3-pyrazol-1-yl-propyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;2-chloro-4-[[3-(2-cyanobutyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyridine-3- carbonitrile;2- chloro-4-[[3-[(3S)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 2-[[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]methyl]cyclopentanecarboxylate;Methyl (2f?)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate;A / -[3-[6-[(2-Chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-1- methyl-propyl]acetamide;5-Chloro- / V-ethyl-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxamide;5-[[5-Chloro-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3- methyl-butyl)-1-methyl-benzimidazol-2-one;5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-1 H-pyrazole-4-carboxylate;ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-3,5-dimethyl-1 H-pyrazole-4- carboxylate;5-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3,5-dihydroxy- 3-methylpentyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylpentyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(dimethylamino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3-hydroxy-4-methoxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4- carboxamide;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-4- methoxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3,5-dihydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;1-(5-chloro-4-((3-(3-hydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;5-((5-chloro-2-(1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5- ((5-chloro-2-(4-chloro-3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;6- (3,5-dimethyl-1 H-pyrazol-1-yl)-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo- 2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)-6-methylpyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-bromo-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-methyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(5-methyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1 H-indazol-3-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1 H-indazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((3-(2-(1-hydroxycyclobutyl)ethyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-(2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-2-oxo-3-(3-oxopentyl)-2,3-dihydro-1 H-benzo[d]imidazol-5- yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-((2-methyltetrahydrofuran-3-yl)methyl)-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-(2-(2-methyl-1 ,3-dioxolan-2-yl)ethyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;tert-butyl 2-((6-((2-chloro-3-cyanopyridin-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-1-yl)methyl)azetidine-1-carboxylate;5-((6-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-3-methyl-2- oxo-2,3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-(2-hydroxypropan-2-yl)-3- methyloxazolidin-2-one;1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;5-((5-chloro-2-(piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(isopropylamino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(ethyl(methyl)amino)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,2-dimethyl-6-(trifluoromethyl)morpholino)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl- 2-0X0-2, 3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3-methyloxazolidin-2- one;5-((6-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3- methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3- methyloxazolidin-2-one;5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl- 2-0X0-2, 3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one;5-((6-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3- methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one;5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-6-fluoro-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-morpholinopyrimidin-4-yl)arriino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2S,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)arriino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2R,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(methylthio)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-bromo-5-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((3-((5-ethyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;4- chloro-6-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidine-5-carbonitrile;2-chloro-4-((3-((5-ethyl-3-methyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2- chloro-4-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;5- ((2,5-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylpentyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloropyrazolo[1 ,5-a]pyrimidin-7-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;3- (3-hydroxy-3-methylbutyl)-1-methyl-5-((2,5,6-trichloropyrimidin-4-yl)amino)-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;(R)-6-chloro-5-cyano-4-((3-(3-methoxybutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)-N-methylpicolinamide;4- ((3-(3-acetamido-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5- yl)amino)-6-chloro-5-cyano-N-methylpicolinamide;5-((5,6-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((3-(((1S,2S)-2-ethyl-2-hydroxycyclopentyl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(((1S,2S)-2-hydroxy-2-methylcyclopentyl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(1-methyl-1 H-pyrazol-3-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1 ,3-dimethyl-1 H-pyrazol-5-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,4-dimethylthiazol-5-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(thiophen-2-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1-methyl-1 H-imidazol-2-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((1-methyl-2-oxo-3-((4-(2,2,2-trifluoroethyl)morpholin-3-yl)methyl)-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(2-(dimethylamino)butyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-ethylpyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-2-oxo-3-((1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-(2-fluoroethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-(2-hydroxyethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(((2R,4S)-4-fluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl)methyl)-1- methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-(ethylamino)butyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-3-methylhex-5-yn-1-yl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-4-methoxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-2-oxo-3-(4,4,4-trifluoro-3-hydroxy-3-methylbutyl)-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-2,3-dimethylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-3,4-dimethylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2-(trifluoromethyl)morpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((3-chloro-2-fluoropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;5-((2,3-dichloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;5-((3-bromopyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro- 2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(trifluoromethyl)pyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((3-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro- 2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2-oxopyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;(S)-5-((5-chloro-2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;(S)-7-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)-5-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1 ,5- a]pyrimidine-3-carbonitrile;2-chloro-4-((1-methyl-3-(2-(2-methyloxiran-2-yl)ethyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(2-(3,5-dimethyl-2-oxooxazolidin-5-yl)ethyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-((5-methyl-2-oxooxazolidin-4-yl)methyl)-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1-methyl-3-((1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl)methyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2- one;5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)- 1 ,3-bis(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1 ,3-bis(3- hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyrimidin-4-yl)arTiino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,2-difluoro-7-azaspiro[3.5]nonan-7-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyridin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;(R)-2-chloro-4-((3-(3-hydroxybutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-(2,2-difluoroethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoro-3-(methoxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3R,4S)-3,4-difluoropyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-((1 R,5S)-8-azabicyclo[3.2.1]octan-8-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-((1 R,5S)-3-azabicyclo[3.2.1]octan-3-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3aR,7aS)-octahydro-2H-isoindol-2-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5- ((5-chloro-2-((3R,4S)-3,4-dimethylpyrrolidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;6- ((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1 ,3-bis(3- hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;6-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)- 1 ,3-bis(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;5-((5-chloro-2-(8,8-difluoro-3-azabicyclo[3.2.1]octan-3-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-((1 r,3r,5r,7r)-2-azaadamantan-2-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;4- chloro-6-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1 ,3- bis(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5- ((5-chloro-2-(3-(methoxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3-hydroxy-5-methylpiperidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3R,5S)-3,5-dimethylazepan-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-phenylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-(4-((1 H-pyrazol-1-yl)methyl)piperidin-1-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3R,5S)-3,5-dimethylpiperidine-1-carbonyl)pyridin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidine-1-carbonyl)pyridin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2- one;5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-1-(2-(dimethylamino)ethyl)-3-(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H- benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-(2-morpholinoethyl)-1 ,3-dihydro-2H- benzo[d]imidazol-2-one;ethyl (E)-4-(5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-1- yl)but-2-enoate;5- ((5-Chloro-2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-[[5-chloro-2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]pyrimidin-4-yl]arTiino]-1- (2-hydroxyethyl)-3-(3-hydroxy-3-methyl-butyl)benzimidazol-2-one;5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)arTiino)-1-(2,2-dimethoxyethyl)-3-(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H- benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)piperidine-4-carbonitrile;1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)piperidine-3-carbonitrile;5-((5-chloro-2-(4-(morpholinomethyl)piperidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-(morpholinomethyl)piperidin-1-yl)pyrimidin-4-yl)amhydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2-methyl-2,4,57-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyrimidin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol- 2-one;5- ((5-chloro-2-(1-methyl-1 ,4,57-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyrimidin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2- one;5- ((5-chloro-2-(3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4-morpholinopiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-(4-(1 H-pyrazol-1-yl)piperidin-1-yl)-5-chloropyrimidin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one; or5- ((5-chloro-2-(2-(hydroxymethyl)morpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- rnethylbutyl)-1-rnethyl-1 ,3-dihydro-2H-benzo[d]irnidazol-2-one.

[0091] Particular compounds of the present invention include any of the compounds exemplified in the present application, or a pharmaceutically acceptable salt or solvate thereof, and, in particular, any of the following:6- Chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]- / V-methyl-pyridine-2-carboxamide;2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]- 6-methyl-pyridine-3-carbonitrile;6-chloro-5-cyano-4-[(1 ,3-dimethyl-2-oxo-benzimidazol-5-yl)amino]pyridine-2- carboxylic acid;6-chloro-5-cyano- / V-methyl-4-[[1-methyl-2-oxo-3-[(3S)-3-pyrazol-1- ylbutyl]benzimidazol-5-yl]amino]pyridine-2-carboxamide;6-chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylic acid;6-chloro-5-cyano- / V-methyl-4-[(1-methyl-2-oxo-3 / - / -benzimidazol-5- yl)amino]pyridine-2-carboxamide;6-chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-2-oxo-1-(tetrahydropyran-4- ylmethyl)benzimidazol-5-yl]amino]- / \ / -methyl-pyridine-2-carboxamide;Ethyl 7-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]- pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3- methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-butanoate;2-bromo-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;2-chloro-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]-6- methyl-pyridine-3-carbonitrile;5-[(2,5-dichloro-4-pyridyl)amino]-3-[(3f?)-3-hydroxybutyl]-1-methyl-benzimidazol-2- one;5-[(2,5-dichloropyrimidin-4-yl)amino]-3-(3-hydroxy-3-methyl-butyl)-1-methyl- benzimidazol-2-one;Ethyl 7-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyrazolo- [1 ,5-a]pyrimidine-5-carboxylate;4- chloro-6-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrimidine-5-carbonitrile;5- [(2,3-dichloro-4-pyridyl)amino]-3-[(3f?)-3-hydroxybutyl]-1-methyl-benzimidazol-2- one;Ethyl 3-fluoro-7-((3-(2-hydroxybutyl)-1-methyl-2-oxo-2,3-dihydro-1 / - / -benzo[d]- imidazol-5-yl)amino)pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;Methyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Ethyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Isopropyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Ethyl 6-chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylate;6- Chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylic acid;Methyl 3-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-propanoate;Methyl 4-[6-[(5-chloro-2-methyl-pyrimidin-4-yl)amino]-3-methyl-2-oxo-benzimidazol- 1 -yl]-2-methyl-butanoate;6-Chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]-N-methyl-pyridine-2-carboxamide;Methyl 4-[6-[[2-chloro-3-cyano-6-(3-methyl-1 ,2,4-oxadiazol-5-yl)-4-pyridyl]amino]-3- methyl-2-oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl (2S)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate;Methyl 4-[6-[[2-chloro-3-cyano-6-(methylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl 4-[6-[[6-(but-3-ynylcarbamoyl)-2-chloro-3-cyano-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl 4-[6-[[2-chloro-3-cyano-6-(dimethylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;6-Chloro-5-cyano-N-[2-(dimethylamino)ethyl]-4-[(1 ,3-dimethyl-2-oxo-benzimidazol- 5-yl)amino]pyridine-2-carboxamide;Ethyl 7-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-hydroxy-butanoate;2-Chloro-4-[[3-(2,3-dihydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methoxy-butanoate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-ethoxy-butanoate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]butanoate;methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-(cyclopropylmethoxy)butanoate;2-chloro-4-[[3-(2-hydroxy-3-pyrazol-1-yl-propyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;2-chloro-4-[[3-(2-cyanobutyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyridine-3- carbonitrile;2-chloro-4-[[3-[(3S)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 2-[[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]methyl]cyclopentanecarboxylate;Methyl (2f?)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate;A / -[3-[6-[(2-Chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzirTiidazol-1-yl]-1- methyl-propyl]acetamide;5-Chloro- / V-ethyl-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxamide;5-[[5-Chloro-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]arriino]-3-(3-hydroxy-3- methyl-butyl)-1-methyl-benzimidazol-2-one;5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)- 3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-1 H-pyrazole-4-carboxylate;ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrirriidiri-2-yl)-3,5-dimethyl-1 l-l-pyrazole-4- carboxylate;5-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arTiino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3,5-dihydroxy- 3-methylpentyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylpentyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(dimethylamino)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3-hydroxy-4-methoxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)pyrimidiri-2-yl)-N,N-dimethylpiperidine-4- carboxamide;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-4- methoxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3,5-dihydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;1- (5-chloro-4-((3-(3-hydroxy-3-methylpebenzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;5-((5-chloro-2-(1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5- ((5-chloro-2-(4-chloro-3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;6- (3,5-dimethyl-1 H-pyrazol-1-yl)-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo- 2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)-6-methylpyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-bromo-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-methyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(5-methyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1 H-indazol-3-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1 H-indazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;2- chloro-4-((3-(2-(1-hydroxycyclobutyl)ethyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-(2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-2-oxo-3-(3-oxopentyl)-2,3-dihydro-1 H-benzo[d]imidazol-5- yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-((2-methyltetrahydrofuran-3-yl)methyl)-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-(2-(2-methyl-1 ,3-dioxolan-2-yl)ethyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;tert-butyl 2-((6-((2-chloro-3-cyanopyridin-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-1-yl)methyl)azetidine-1-carboxylate;5-((6-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-3-methy oxo-2,3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-(2-hydroxypropan-2-yl)-3- methyloxazolidin-2-one;1- (5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;5-((5-chloro-2-(piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(isopropylamino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-methylpiperidin-1-yl)pyrimidin-4-yl)arTiino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(ethyl(methyl)amino)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,2-dimethyl-6-(trifluoromethyl)morpholino)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl-2- 0X0-2, 3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3-methyloxazolidin-2- one;5-((6-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3- methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3- methyloxazolidin-2-one;5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl- 2-0X0-2, 3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one;5-((6-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arTiino)-3- methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one;5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-6-fluoro-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-morpholinopyrimidin-4-yl)arriino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2S,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)arriino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2R,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)arriino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(methylthio)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-bromo-5-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((3-((5-ethyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;4- chloro-6-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidine-5-carbonitrile;2-chloro-4-((3-((5-ethyl-3-methyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2- chloro-4-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;5- ((2,5-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylpentyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloropyrazolo[1 ,5-a]pyrimidin-7-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;3- (3-hydroxy-3-methylbutyl)-1-methyl-5-((2,5,6-trichloropyrimidin-4-yl)amino)-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;(R)-6-chloro-5-cyano-4-((3-(3-methoxybutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)-N-methylpicolinamide;4- ((3-(3-acetamido-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5- yl)amino)-6-chloro-5-cyano-N-methylpicolinamide;5-((5,6-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((3-(((1S,2S)-2-ethyl-2-hydroxycyclopentyl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(((1S,2S)-2-hydroxy-2-methylcyclopentyl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(1-methyl-1 H-pyrazol-3-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1 ,3-dimethyl-1 H-pyrazol-5-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,4-dimethylthiazol-5-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(thiophen-2-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1-methyl-1 H-imidazol-2-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((1-methyl-2-oxo-3-((4-(2,2,2-trifluoroethyl)morpholin-3-yl)methyl)-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(2-(dimethylamino)butyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-ethylpyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-2-oxo-3-((1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-(2-fluoroethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-(2-hydroxyethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(((2R,4S)-4-fluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl)methyl)-1- methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-(ethylamino)butyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-3-methylhex-5-yn-1-yl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-4-methoxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-2-oxo-3-(4,4,4-trifluoro-3-hydroxy-3-methylbutyl)-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-2,3-dimethylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-3,4-dimethylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2-(trifluoromethyl)morpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((3-chloro-2-fluoropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;5-((2,3-dichloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;5-((3-bromopyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro- 2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(trifluoromethyl)pyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((3-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro- 2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2-oxopyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;(S)-5-((5-chloro-2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;(S)-7-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)-5-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1 ,5- a]pyrimidine-3-carbonitrile;2-chloro-4-((1-methyl-3-(2-(2-methyloxiran-2-yl)ethyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(2-(3,5-dimethyl-2-oxooxazolidin-5-yl)ethyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-((5-methyl-2-oxooxazolidin-4-yl)methyl)-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1-methyl-3-((1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl)methyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2- one;5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)- 1 ,3-bis(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1 ,3-bis(3- hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyrimidin-4-yl)arTiino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,2-difluoro-7-azaspiro[3.5]nonan-7-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one; or1- (5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyridin-2-yl)-N,N-dimethylpiperidine-4-carboxamide.

[0092] Particular compounds of the present invention include any of the compounds exemplified in the present application, or a pharmaceutically acceptable salt or solvate thereof, and, in particular, any of the following:6-Chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]- / V-methyl-pyridine-2-carboxamide;2- chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]- 6-methyl-pyridine-3-carbonitrile;6-chloro-5-cyano-4-[(1 ,3-dimethyl-2-oxo-benzimidazol-5-yl)amino]pyridine-2- carboxylic acid;6-chloro-5-cyano- / V-methyl-4-[[1-methyl-2-oxo-3-[(3S)-3-pyrazol-1- ylbutyl]benzimidazol-5-yl]amino]pyridine-2-carboxamide;6-chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylic acid;6-chloro-5-cyano- / V-methyl-4-[(1-methyl-2-oxo-3 / - / -benzimidazol-5- yl)amino]pyridine-2-carboxamide;6-chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-2-oxo-1-(tetrahydropyran-4- ylmethyl)benzimidazol-5-yl]amino]- / \ / -methyl-pyridine-2-carboxamide;Ethyl 7-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]- pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3- methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-butanoate;2-bromo-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;2-chloro-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]-6- methyl-pyridine-3-carbonitrile;5-[(2,5-dichloro-4-pyridyl)amino]-3-[(3f?)-3-hydroxybutyl]-1-methyl-benzimidazol-2- one;5-[(2,5-dichloropyrimidin-4-yl)amino]-3-(3-hydroxy-3-methyl-butyl)-1-methyl- benzimidazol-2-one;Ethyl 7-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyrazolo- [1 ,5-a]pyrimidine-5-carboxylate;4- chloro-6-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrimidine-5-carbonitrile;5- [(2,3-dichloro-4-pyridyl)amino]-3-[(3f?)-3-hydroxybutyl]-1-methyl-benzirriidazol-2- one;Ethyl 3-fluoro-7-((3-(2-hydroxybutyl)-1-methyl-2-oxo-2,3-dihydro-1 / - / -benzo[d]- imidazol-5-yl)amino)pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;Methyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Ethyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Isopropyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Ethyl 6-chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylate;6- Chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylic acid;Methyl 3-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-propanoate;Methyl 4-[6-[(5-chloro-2-methyl-pyrimidin-4-yl)amino]-3-methyl-2-oxo-benzimidazol- 1 -yl]-2-methyl-butanoate;6-Chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]-N-methyl-pyridine-2-carboxamide;Methyl 4-[6-[[2-chloro-3-cyano-6-(3-methyl-1 ,2,4-oxadiazol-5-yl)-4-pyridyl]amino]-3- methyl-2-oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl (2S)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate;Methyl 4-[6-[[2-chloro-3-cyano-6-(methylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl 4-[6-[[6-(but-3-ynylcarbamoyl)-2-chloro-3-cyano-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl 4-[6-[[2-chloro-3-cyano-6-(dimethylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;6-Chloro-5-cyano-N-[2-(dimethylamino)ethyl]-4-[(1 ,3-dimethyl-2-oxo-benzirnidazol- 5-yl)amino]pyridine-2-carboxamide;Ethyl 7-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)arnino]-3-methyl-2-oxo-benzirnidazol-1-yl]- 2-hydroxy-butanoate;2-Chloro-4-[[3-(2,3-dihydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methoxy-butanoate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-ethoxy-butanoate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]butanoate;methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-(cyclopropylmethoxy)butanoate;2-chloro-4-[[3-(2-hydroxy-3-pyrazol-1-yl-propyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;2-chloro-4-[[3-(2-cyanobutyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyridine-3- carbonitrile;2-chloro-4-[[3-[(3S)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 2-[[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]methyl]cyclopentanecarboxylate;Methyl (2f?)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate;A / -[3-[6-[(2-Chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-1- methyl-propyl]acetamide;5-Chloro- / V-ethyl-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxamide; or5-[[5-Chloro-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3- methyl-butyl)-1-methyl-benzimidazol-2-one.

[0093] The various functional groups and substituents making up the compounds of the Formula (I), or sub-formulae la to Ij, are typically chosen such that the molecular weight of the compound of the formula (I) does not exceed 1000. More usually, the molecular weight of the compound will be less than 900, for example less than 800, or less than 750, or less than 700, or less than 650. More preferably, the molecular weight is less than 600 and, for example, is 550 or less.

[0094] A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, forexample, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric, methane sulfonate or maleic acid. In addition, a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

[0095] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers". Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".

[0096] The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of a racemic form. Some of the compounds of the invention may have geometric isomeric centres (E- and Z- isomers). It is to be understood that the present invention encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof that possess antiproliferative activity.

[0097] The present invention also encompasses compounds of the invention as defined herein which comprise one or more isotopic substitutions. For example, H may be in anyisotopic form, including 1 H, 2H(D), and 3H (T); C may be in any isotopic form, including 12C, 13C, and 14C; and O may be in any isotopic form, including 160 and180; and the like.

[0098] It is also to be understood that certain compounds of the Formula (I), or sub-formulae la to Ij, may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms that possess antiproliferative activity.

[0099] It is also to be understood that certain compounds of the Formula I, or sub-formulae la to Ij, may exhibit polymorphism, and that the invention encompasses all such forms that possess antiproliferative activity.

[0100] Compounds of the Formula I, or sub-formulae la to Ij, may exist in a number of different tautomeric forms and references to compounds of the Formula I, or sub-formulae la to Ij, include all such forms. For the avoidance of doubt, where a compound can exist in one of several tautomeric forms, and only one is specifically described or shown, all others are nevertheless embraced by Formula I, or sub-formulae la to Ij. Examples of tautomeric forms include keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto / enol (illustrated below), imine / enamine, amide / imino alcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, and nitro / aci-nitro.— c-c c=c ^ c=cI \ / \ H+ / \keto enol enolate

[0101] Compounds of the Formula I, or sub-formulae la to Ij, containing an amine function may also form N-oxides. A reference herein to a compound of the Formula I, or sub-formulae la to Ij, that contains an amine function also includes the N-oxide. Where a compound contains several amine functions, one or more than one nitrogen atom may be oxidised to form an N- oxide. Particular examples of N-oxides are the N-oxides of a te / fiary amine or a nitrogen atom of a nitrogen-containing heterocycle. N-Oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages. More particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with m-chloroperoxybenzoic acid (mCPBA), for example, in an inert solvent such as dichloromethane.

[0102] The compounds of Formula (I), or sub-formulae la to Ij, may be administered in the form of a pro-drug which is broken down in the human or animal body to release a compoundof the invention. A pro-drug may be used to alter the physical properties and / or the pharmacokinetic properties of a compound of the invention. A pro-drug can be formed when the compound of the invention contains a suitable group or substituent to which a property- modifying group can be attached. Examples of pro-drugs include in vivo cleavable ester derivatives that may be formed at a carboxy group or a hydroxy group in a compound of the Formula (I), or sub-formulae la to Ij, and in-vivo cleavable amide derivatives that may be formed at a carboxy group or an amino group in a compound of the Formula (I), or sub- formulae la to Ij.

[0103] Accordingly, the present invention includes those compounds of the Formula (I), or sub-formulae la to Ij, as defined hereinbefore, when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the Formula I, or sub-formulae la to Ij, that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the Formula (I), or sub-formulae la to Ij, may be a synthetically-produced compound or a metabolically-produced compound.

[0104] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula (I), or sub-formulae la to Ij, is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.

[0105] Various forms of pro-drug have been described, for example in the following documents:- a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985);b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985);c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen andH. Bundgaard, Chapter 5 "Design and Application of Pro-drugs", by H. Bundgaard p. 1 13-191 (1991);H Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984);9) J. Rautio, et al. Nature Reviews Drug Discovery (2018);h) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", A.C.S. Symposium Series, Volume 14; andi) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.

[0106] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula I, or sub-formulae la to Ij, that possesses a carboxy group is, for example, an in vivo cleavable ester thereof. An in vivo cleavable ester of a compound of the Formula I, or sub-formulae la to Ij, containing a carboxy group is, for example, a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid. Suitable pharmaceutically acceptable esters for carboxy include C1-6alkyl esters such as methyl, ethyl and te / f-butyl, C1-6alkoxymethyl esters such as methoxymethyl esters, C1-6alkanoyloxymethyl esters such as pivaloyloxymethyl esters, 3-phthalidyl esters, C3-8cycloalkylcarbonyloxy- C1-6alkyl esters such as cyclopentylcarbonyloxymethyl and 1-cyclohexylcarbonyloxyethyl esters, 2-OXO-1 , 3-dioxolenylmethyl esters such as 5-methyl-2-oxo-1 ,3-dioxolen-4-ylmethyl esters and C1-6alkoxycarbonyloxy- C1-6alkyl esters such as methoxycarbonyloxymethyl and 1- methoxycarbonyloxyethyl esters.

[0107] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula (I), or sub-formulae la to Ij, that possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof. An in vivo cleavable ester or ether of a compound of the Formula I, or sub-formulae la to Ij, containing a hydroxy group is, for example, a pharmaceutically acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy compound. Suitable pharmaceutically acceptable ester forming groups for a hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters). Further suitable pharmaceutically acceptable ester forming groups for a hydroxy group include C1-10alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, C1-10alkoxycarbonyl groups such as ethoxycarbonyl, N,N -(C1-6)2carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N- alkylaminomethyl, Ν,Ν-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4- (C1-4alkyl)piperazin-1-ylmethyl. Suitable pharmaceutically acceptable ether forming groups for a hydroxy group include a-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.

[0108] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula (I), or sub-formulae la to Ij, that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as ammonia, a C1- 4alkylamine such as methylamine, a (C1-4alkyl)2amine such as dimethylamine, N-ethyl-N-methylamine or diethylamine, a C1-4alkoxy- C2-4alkylamine such as 2-methoxyethylamine, a phenyl-C1-4alkylamine such as benzylamine and amino acids such as glycine or an ester thereof.

[0109] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula I, or sub-formulae la to Ij, that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof. Suitable pharmaceutically acceptable amides from an amino group include, for example an amide formed with C1-10alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N- dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and4-(C1-4alkyl)piperazin-1-ylmethyl.

[0110] The in vivo effects of a compound of the Formula (I), or sub-formulae la to Ij, may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the Formula (I), or sub-formulae la to Ij. As stated hereinbefore, the in vivo effects of a compound of the Formula (I), or sub-formulae la to Ij, may also be exerted by way of metabolism of a precursor compound (a pro-drug).

[0111] Though the present invention may relate to any compound or particular group of compounds defined herein by way of optional, preferred or suitable features or otherwise in terms of particular embodiments, the present invention may also relate to any compound or particular group of compounds that specifically excludes said optional, preferred or suitable features or particular embodiments.

[0112] Suitably, the present invention excludes any individual compounds not possessing the biological activity defined herein.Synthesis

[0113] The compounds of the present invention can be prepared by any suitable technique known in the art. Particular processes for the preparation of these compounds are described further in the accompanying examples.

[0114] In the description of the synthetic methods described herein and in any referenced synthetic methods that are used to prepare the starting materials, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be selected by a person skilled in the art.

[0115] It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions utilised.

[0116] It will be appreciated that during the synthesis of the compounds of the invention in the processes defined herein, or during the synthesis of certain starting materials, it may be desirable to protect certain substituent groups to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and how such protecting groups may be put in place, and later removed.

[0117] For examples of protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with the minimum disturbance of groups elsewhere in the molecule.

[0118] Thus, if reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

[0119] By way of example, a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed by, for example, hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively, an acyl group such as a te / f-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

[0120] A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protectinggroups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia. Alternatively, an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

[0121] A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

[0122] Resins may also be used as a protecting group.

[0123] The methodology employed to synthesise a compound of Formula (I), or sub- formulae la to Ij, will vary depending on the nature of Xi , X2, R\ R2, R3and any substituent groups associated therewith. Suitable processes for their preparation are described further in the accompanying Examples.

[0124] Once a compound of Formula (I), or sub-formulae la to Ij, has been synthesised by any one of the processes defined herein, the processes may then further comprise the additional steps of:(i) removing any protecting groups present;(ii) converting the compound Formula (I) into another compound of Formula (I);(iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and / or(iv) forming a prodrug thereof.

[0125] An example of (ii) above is when a compound of Formula (I) is synthesised and then one or more of the groups of Xi , X2, R\ R2, R3may be further reacted to change the nature of the group and provide an alternative compound of Formula (I). For example, the compound can be reacted to convert any R group into a substituent group other than hydrogen.

[0126] The resultant compounds of Formula (I), or sub-formulae la to Ij, can be isolated and purified using techniques well known in the art.

[0127] The compounds of Formula (I) may be synthesised by the general synthetic routes (e.g. Schemes 1 to 7) below, specific examples of which are described in more detail in the Examples.Scheme 1wherein, Y is a halogen such as CI, Br, I or a suitable alternative such as OTf, and R1, R2, R3, Xi , X2 are appropriate groups chosen from those defined previously.

[0128] The reaction between aromatic amines (II) and aryl halides or appropriate equivalent reagents (III) to form compounds of formula (I) as shown in Scheme 1 may be carried out at elevated temperature (e.g. 60-180 °C), using conventional or microwave heating, in a suitable solvent or solvent mixture, such as NMP, DMA, DMF, dioxane or acetonitrile. The reaction is carried out in the presence of a base (such as triethylamine or DIPEA) or with no base. Alternative reaction conditions include the use of a transition metal catalyst such as Pd2(dba)3 combined with a suitable ligand such as Xantphos, in the presence of a base such as cesium carbonate at elevated temperature (such as 140 °C), using a suitable solvent or solvent mixture, such as toluene or mixtures of toluene and DMF or NMP.

[0129] A compound of formula (I) may be converted to another compound of formula (I) by methods generally known to those skilled in the art.

[0130] Compounds of formula (II) may be obtained from commercial suppliers, prepared as described in Scheme 2 or by other methods known in the art. Compounds (III) may be obtained from commercial suppliers or prepared by reported methods.Scheme 2(IV) (ll) wherein, R1, R2, R3, Xi , X2 are appropriate groups chosen from those defined previously.

[0131] The reduction of nitro compounds (IV) to aromatic amines (II) may be carried out by numerous methods which are well known in the art. Hydrogenation can be carried out in the presence of a metal catalyst such as palladium, typically on carbon support, in an appropriate solvent or mixture of solvents such as ethanol, methanol, ethyl acetate or ethanol / NMP atambient or elevated temperature (such as 60 - 75 °C) using conventional or microwave heating. These reactions are carried out under a hydrogen atmosphere, or alternatively by "transfer hydrogenation" using a reagent such as ammonium formate or triethylsilane. Other approaches are known in the art including the use of tin chloride, iron or zinc metal mediated reductions. Compounds of formula (IV) may be obtained from commercial suppliers, prepared by methods shown in Scheme 3 or by other methods known in the art.Scheme 3wherein, Y2is a halogen such as CI, Br, I or a suitable alternative such as OTs, OMs and R1, R2, W2, Xi , X2 are appropriate groups chosen from those defined previously.

[0132] Introduction of R2group onto compounds (V) may be carried out by alkylation to form compounds (IV). Alkylation conditions are well known in the art, and include the use of an alkyl halide, tosylate or equivalent (Y2-R2, such as iodomethane or 3-hydroxy-3-methyl-butyl 4-methylbenzenesulfonate) in an appropriate solvent such as acetonitrile or DMF, in the presence of a base such as cesium carbonate, at ambient or elevated temperature (e.g. 60 - 100 °C). Where Y2is not iodide, potassium iodide may be added to the reaction conditions to increase the rate of reaction. Alternative alkylating agents such as epoxides may be used for form compounds of formula (IV), specifically those with structure (IVa). Similarly, compounds (IV) may be formed by alkylation of compounds (VI) with alkylating agent Y2-R1, or with epoxides or with other appropriate reagents. Particularly where R1= R2, compounds (IV) can be formed by successive alkylations starting from compounds where R1=R2=H. Where R1and R2are different, this approach may lead to mixtures of compounds which could be separated using known methods. Alternatively, the well-known Mitsunobu reaction may be applied to convert compounds (V) or (VI) into (IV) using an appropriate alcohol R2-OH. Furthermanipulation of compounds (IV) by known methods can be used to modify R1, R2. For example, ring expansion of an epoxide group to an oxazolidinone group by known methods including ring opening with ammonia or an amine, followed by cyclisation with a phosgene equivalent such as triphosgene or disuccinimidyl carbonate. Certain compounds of formula (V) and (VI) are commercially available, or may be prepared using known methods. Nitro compounds such as (IV) (V) and (V), particularly where X2 = F, halo, alkyl, may also be prepared by nitration using known methods. Compounds (V) may also be prepared as described in Scheme 4. Alkylating agents Y2-R1, Y2-R2are commercially available, or prepared as described in Scheme 6 or by known methods such as tosylation or mesylation of an alcohol, or conversion of an alcohol into a halide. Epoxides may be obtained from commercial suppliers or prepared by known methods such as oxidation of alkenes with m- CPBA.Scheme 4(IX) (VIM) (VII) (V) wherein Y is a halogen such as CI, Br, I or a suitable alternative such as OTs, OTf, and R1, Xi , X2 are appropriate groups chosen from those defined previously.

[0133] Compounds (V) may be formed by cyclisation of diamino compounds (VII). Possible conditions include the use of bis(2,5-dioxopyrrolidin-1-yl) carbonate in acetonitrile at ambient temperature, but alternative conditions for these cyclisations are well known in the art using reagents such as carbonyl diimidazole, triphosgene and urea. Compounds (VII) may be formed by reaction of compounds (VIII) with an appropriate amine R1-NH2. Suitable conditions for these transformations include the use of a base (such as DIPEA) in an appropriate solvent (such as NMP) at elevated temperature (such as 180 °C), although many alternative conditions are known by those skilled in the art for this class of transformation including metal- catalysed couplings. Alternatively, the more reactive di-nitro compounds (IX) can be used to prepare (VII) by halogen displacement followed by nitro reduction as described in the literature, for example Freitag et al, Bioorg. Med. Chem. 2011 p3669-3677. Amines R1- Nhb.and nitro-compounds (IX) and (VIII) may be prepared by known methods or obtained from commercial suppliers.Scheme 5wherein, Y is a halogen such as CI, Br, I or a suitable alternative such as OTf, OTs, and R1, R2, R3, Xi , X2 are appropriate groups chosen from those defined previously.Introduction of R2group onto compounds (X) may be carried out by alkylation using compounds (XI) to form compounds (I), using conditions such as those described in Scheme 3 or others known in the art. Similar reagents such as epoxides may also be used to form compounds (I) from (X). The Mitsunobu reaction as described in Scheme 3 may also be used to form certain compounds (I) from (X) using an alcohol R2-OH. In particular, the use of the Mitsunobu reagent CMBP (available from TCI Chemicals) as described in, Pure Appl. Chem. 1999,(71 ), 6, 1053-1057 can enable this reaction to work effectively, despite the relatively weak acidity of compounds (X). Typically, this reaction is carried out at elevated temperature (such as 60-100 °C) in an appropriate solvent or solvent mixture such as DMF and THF.

[0134] Alkylation may occur on the desired or other positions, appropriate choice of reaction conditions may modify selectivity and regioisomers formed may be separable by appropriate use of known purification techniques such as HPLC, flash chromatography and crystallisation. Compounds (X) may be prepared by methods including those described in Scheme 1. Compounds (XI) may be commercially available, prepared as described in Scheme 6 or by known methods such as tosylation or mesylation of an alcohol, or conversion of an alcohol into a halide. Epoxides may be obtained from commercial suppliers or prepared by known methods. Functionality on R2 may be masked in compound (XI) by the use of protecting groups, which can be removed at a later stage in the synthesis. The application of protecting groups is well known in the art. For example, the Schollkopf auxiliary may be used as a protected form of amino acid derivatives as described in Ma et al J. Org. Chem., 2001 , pp 4525-4542.Scheme 6(XIV) (XII) (XV) (XIII) wherein, Y is a halogen such as Br, I and W1, R6, R7, Rq, Racand A are appropriate groups chosen from those defined previously.

[0135] Alkylating agents of the general formula (XII) or (XIII) [equivalent to compounds (XI) for specific R2groups) where Y=iodo may be prepared using conditions analogous to those reported in Bartrum et al, Synlett 2009 p2257-2260, via iodotrimethylsilane-mediated ring opening of the lactone (XIV) or (XV) and quenching of the resultant silyl ester with an alcohol Rq-OH or Rac-OH. Alternatively, ring opening of (XIV) or (XV) with an alcohol such as methanol may be employed to form esters analogous to (XII) and (XIII) except where Y = OH, which can then be further converted into alkylating agents by known methods. This route is exemplified in WO 2009 / 097578 A1 , 2009, p.244-245. (XIV) and (XV) may be obtained from commercial suppliers or prepared by methods known in the art.Scheme 7(lb) (la) (Ic) wherein, Y is a halogen such as CI, Br, I or a suitable alternative such as OTf, OTs, and R1, R2, R3, R9, R10, Xi , X2, Xa, Xb are appropriate groups chosen from those defined previously.

[0136] A compound of formula (I) may be converted to another compound of formula (I) by methods generally known to those skilled in the art. Some examples of this are represented in this scheme. A subset of compounds of formula (I) represented by formula (la) may be formed from compounds of formula (lb) by known methods, including aromatic nucleophilic substitution with an appropriate amine, or with a heterocycle containing an NH (such as a piperidine or morpholine), or with a heteroaryl containing an NH (such as a pyrazole), or withan alcohol. These reactions are typically carried out at elevated temperature, in an appropriate solvent (such as DMF, NMP, ethanol or acetonitrile) and may benefit from the addition of a base (such as cesium or other metal carbonates, DIPEA, triethylamine or sodium hydride), and in some cases by addition of an appropriate metal catalyst and ligand. Metal catalysis may also be used for reactions of (lb) with boronic acids or esters via the well-known Suzuki reaction, or with other organometallic compounds (such as organotin species) in similar reactions (including the Stille reaction). Acids (lc) may be converted into compounds of formula (la) using known methods such as amide or ester formation. Heteroaryls may also be prepared from these compounds (for example, the formation of R10= oxadiazole by condensation of (1c) with amidoximes in the presence of a coupling or dehydrating reagent such as T3P). Similar procedures to those described in this scheme may also be used for modifying other positions of molecules of formula (I) such as the R11group in compounds containing the Formula B substructure as described in the embodiments.Biological Activity

[0137] The biological assays described in the Examples section herein may be used to measure the pharmacological effects of the compounds of the present invention.

[0138] Although the pharmacological properties of the compounds of Formula I vary with structural change, as expected, the compounds of the invention were found to be active in the HTRF in vitro assay described in the Examples section.

[0139] In general, as illustrated by the Example compound data in Table 1 a or Table 1 b, in the HTRF assay described in the Examples section, the compounds of the invention demonstrate an IC50 of 5 μΜ or less, which corresponds to a pICso of 5.3 or more, with preferred compounds of the invention demonstrating an IC50 of 1 μΜ or less, which corresponds to a pICso of 6.0 or more.

[0140] In the NanoBRET cell assay described herein in the Examples section, as illustrated by the Example compound data in Table 2a or Table 2b, the compounds of Formula I typically demonstrate a pICso of 5.0 or more.

[0141] In the immunofluorescence assay described herein in the Examples section, certain compounds of the invention have been shown to enable degradation of BCL6. This is illustrated by the Example compound data shown in Table 2c.

[0142] In general, as illustrated by the Example compound data in Table 2d, compounds of the invention show inhibition of cell proliferation when tested in the assay described herein in the Examples section.

[0143] The following data were generated for the Examples:Table 1a - Initially Generated Data from the HTRF in vitro AssayTable 1 b - Further Generated Data from the HTRF in vitro AssayHTRF HTRF HTRF HTRF HTRFExample Example Example Example ExamplepICso pICso pICso pICso pICso1 a 6.22 12 5.68 20i 6.17 25h 5.55 35o 6.041 c 6.08 14 6.29 20j 6.80 25i 5.71 35p 6.151 f 5.59 15a 6.61 20k 6.1 1 26a 5.41 35q 6.63 i g 5.95 15b 5.96 20I 6.39 27a 5.86 35r 5.981 h 5.94 15c 6.22 20m 5.97 27b 6.14 35s 6.161 i 6.08 15d 6.41 20n 6.42 27c 5.93 35t 6.461j 5.78 15e 6.02 20o 6.22 27d 5.70 35u 5.741 k 5.82 15f 6.00 20p 6.44 27e 5.55 35v 6.7011 5.53 15g 5.89 20q 5.87 27f 5.40 35w 5.741 m 5.47 15h 5.86 20r 6.53 28a 7.06 35x 7.011 n 5.82 15i 6.75 20s 6.26 28b 6.55 35y 5.701 o 5.48 15j 5.76 20t 6.51 29a 6.21 35za 6.001 p 5.56 15k 6.27 21 a 7.00 29b 5.88 35zb 6.49HTRF HTRF HTRF HTRF HTRFExample Example Example Example ExamplepICso pICso pICso pICso pICso1 q 5.45 151 6.63 21 b 7.01 29c 5.38 36a 6.091 r 5.91 15m 6.08 22a 6.19 29d 5.48 36b 5.992a 6.18 15n 6.35 22b 5.65 29e 5.93 36c 5.882b 6.10 15o 5.88 22c 5.76 30a 6.09 36d 5.482d 5.87 15p 5.82 22d 5.45 30b 5.99 36e 6.223a 5.93 15q 6.09 22e 5.88 31 a 6.46 36f 6.073b 5.35 16a 6.38 22f 5.75 31 b 5.73 37a 6.533c 5.37 16b 6.31 22g 5.27 32 5.44 37b 6.474 5.79 17a 6.27 22h 5.47 33 5.43 38a 5.535 6.19 17b 6.21 22i 5.54 34 5.31 39a 6.096 6.00 18a 5.90 22I 5.64 35a 7.15 40a 6.497a 6.09 18b 5.31 22m 5.52 35b 6.70 41 a 6.068 6.01 19a 5.83 22n 5.90 35c 6.53 42a 6.609 5.97 19b 5.55 23a 6.35 35d 6.48 42b 6.4610a 5.93 19c 5.45 23b 6.05 35e 6.71 42c 6.5610b 5.57 19d 5.44 23c 5.99 35f 6.05 42d 6.5410c 5.69 20a 6.46 23d 5.62 35g 6.12 42e 6.6810d 5.29 20b 6.01 24a 6.33 35h 6.36 42f 6.5810e 5.38 20c 6.60 25a 5.58 35i 6.01 42g 6.9210f 5.48 20d 5.92 25b 5.34 35j 5.76 42h 6.8810g 5.45 20e 6.09 25c 5.34 35k 6.56 42i 6.8510h 5.32 20f 5.99 25e 5.37 35I 6.76 42j 6.8110i 5.81 20g 6.07 25f 5.73 35m 6.811 1 5.72 20h 6.49 25g 5.34 35n 6.05Table 2a - Initially Generated Data from the NanoBRET cell assayTable 2b - Further Generated Data from the NanoBRET cell assayNanoBRET cell NanoBRET cell NanoBRET cellExample Example ExamplepICso pICso pICso1 a 5.45 17a 5.94 35e 5.881 b 5.28 17b 5.72 35g 5.654 5.20 20c 5.67 35k 5.8315a 5.75 20j 5.75 35I 5.8215c 5.69 21 a 5.87 35m 6.1315d 5.89 21 b 5.86 35q 5.7715i 5.66 28a 6.25 35t 5.63151 5.88 28b 5.66 35v 5.6315n 5.74 30a 5.51 35x 5.50Table 2c - Data Generated from the Immunofluorescence AssayTable 2d - Data Generated from the Cell Viability Assay

[0144] The following compounds were tested but did not exhibit the desired activity in the HTRF assay described in the Examples section:1 ,3-dimethyl-5-((3-(trifluoromethyl)pyridin-4-yl)amino)-1 ,3-dihydro-2H- benzo[d]imidazol-2-one1 ,3-dimethyl-5-((5-methylpyrimidin-4-yl)amino)-1 ,3-dihydro-2H-benzo[d]imidazol-2- one5-((6-chloro-5-methoxypyrimidin-4-yl)amino)-1 ,3-dimethyl-1 ,3-dihydro-2H- benzo[d]imidazol-2-one4- ((1 ,3-dimethyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)pyrimidine-5- carbonitrile2-chloro-4-((1-methyl-3-(2-morpholinoethyl)-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5- yl)amino)nicotinonitrile2-chloro-4-((3-(2-(diethylamino)ethyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile1-methyl-3-phenethyl-5-(pyrazolo[1 ,5-a]pyrimidin-7-ylamino)-1 ,3-dihydro-2H- benzo[d]imidazol-2-one4-((1 ,3-dimethyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)-2- methylnicotinonitrile2-chloro-4-((1-methyl-2-oxo-3-((tetrahydro-2H-pyran-4-yl)methyl)-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile2-chloro-4-((1-methyl-2-oxo-3-(piperidin-4-ylmethyl)-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile2-chloro-4-((3-(2-hydroxy-3,3-dimethylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile1 ,3-dimethyl-5-((5-(trifluoromethyl)-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-7-yl)amino)-1 ,3- dihydro-2H-benzo[d]imidazol-2-one4- ((1 ,3-dimethyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)-2- (trifluoromethyl)nicotinonitrile5- ((5-((2-methoxyethyl)amino)pyrazolo[1 ,5-a]pyrimidin-7-yl)amino)-1 ,3-dimethyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one2- chloro-4-((3-(2-hydroxy-2-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile5-((2-chloro-5-(difluoromethyl)pyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one5-((2-chloro-3-(trifluoromethyl)pyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one5- ((2-chloro-3-(difluoromethyl)pyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one6- ((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyrimidin-4-yl)arTiino)-1-(3-hydroxy-3- methylbutyl)-3-methyl-1 ,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one6-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyridin-4-yl)amino)-1-(3-hydroxy-3- methylbutyl)-3-methyl-1 ,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one6-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-1-(3-hydroxy-3- methylbutyl)-3-methyl-1 ,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one6-((2,5-dichloropyrimidin-4-yl)amino)-1-(3-hydroxy-3-methylbutyl)-3-methyl-1 ,3- dihydro-2H-imidazo[4,5-c]pyridin-2-one6-((3-chloropyridin-4-yl)amino)-1-(3-hydroxy-3-methylbutyl)-3-methyl-1 ,3-dihydro-2H- imidazo[4,5-c]pyridin-2-one6-((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyridin-4-yl)amino)-1-(3-hydroxy-3- methylbutyl)-3-methyl-1 ,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one(R)-2-chloro-4-((1-methyl-3-((1-methylpyrrolidin-2-yl)methyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile5-((3,5-dichloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro- 2H-benzo[d]imidazol-2-one5-((6-chloroimidazo[1 ,2-a]pyridin-7-yl)am1 ,3-dihydro-2H-benzo[d]imidazol-2-one2-chloro-4-((3-((3-(hydroxymethyl)oxetan-3-yl)methyl)-1-methyl-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile2-chloro-4-((3-((4-cyanotetrahydro-2H-pyran-4-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]irnidazol-5-yl)arnino)nicotinonitrile2-chloro-4-((1-methyl-2-oxo-3-(piperidin-3-ylmethyl)-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile4- ((3-(azetidin-2-ylmethyl)-1-methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5- yl)amino)-2-chloronicotinonitrile2-chloro-4-((3-((3,3-dimethylcyclobutyl)methyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile5- ((2,5-dichloropyrimidin-4-yl)amino)-3-(3,5-dihydroxy-3-methylpentyl)-1-methyl-1^dihydro-2H-benzo[d]imidazol-2-onetert-butyl 3-((6-((2-chloro-3-cyanopyridin-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-1-yl)methyl)piperidine-1-carboxylate(S)-2-chloro-4-((3-((1-(cyclopropylmethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]irnidazol-5-yl)arnino)nicotinonitrile2-chloro-4-((3-((2,2-dimethyltetrahydrofuran-3-yl)methyl)-1-methyl-2-oxo-2,3-dihyd 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile

[0145] In an embodiment, the compounds of the invention are compounds of formula I as defined hereinbefore, with the proviso that the compound is not one of the compounds listed in the preceding paragraph.Pharmaceutical Compositions

[0146] According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the invention as defined hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.

[0147] The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as asterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing).

[0148] The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and / or preservative agents.

[0149] An effective amount of a compound of the present invention for use in therapy is an amount sufficient to treat or prevent a proliferative condition referred to herein, slow its progression and / or reduce the symptoms associated with the condition.

[0150] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the individual treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.

[0151] The size of the dose for therapeutic or prophylactic purposes of a compound of the formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.

[0152] In using a compound of the invention for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg / kg to 75 mg / kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous or intraperitoneal administration, a dose in the range, for example, 0.1 mg / kg to 30 mg / kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg / kg to 25 mg / kg body weight will be used. Oral administration may also be suitable, particularly in tablet form. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.Therapeutic Uses and Applications

[0153] The present invention provides compounds that function as inhibitors of BCL6.

[0154] The present invention therefore provides a method of inhibiting BCL6 activity in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound,or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.

[0155] The present invention also provides a method of treating a disease or disorder in which BCL6 activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0156] The present invention provides a method of inhibiting cell proliferation, in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.

[0157] The present invention provides a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0158] The present invention provides a method of treating cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0159] The present invention provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in therapy.

[0160] The present invention provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the treatment of a proliferative condition.

[0161] The present invention provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the treatment of cancer. In a particular embodiment, the cancer is human cancer.

[0162] The present invention provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the inhibition of BCL6 activity (i.e. in the inhibition of BCL6 transcriptional repression and / or co-repressor binding).

[0163] Certain compounds of the present invention have been found to bind to BCL6 and initiated the degradation of BCL6. Thus, the present invention also provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the degradation of BCL6.

[0164] The present invention provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the treatment of a disease or disorder in which BCL6 activity is implicated.

[0165] The present invention provides a use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a proliferative condition.

[0166] The present invention provides a use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of cancer. Suitably, the medicament is for use in the treatment of human cancers.

[0167] The present invention provides a use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the inhibition of BCL6 activity (i.e. in the inhibition of BCL6 transcriptional repression and / or co-repressor binding).

[0168] The present invention provides a use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the degradation BCL6.

[0169] The present invention provides a use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a disease or disorder in which BCL6 activity is implicated.

[0170] The term "proliferative disorder" and "proliferative condition" are used interchangeably herein and pertain to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro ox in vivo. Examples of proliferative conditions include, but are not limited to, pre-malignant and malignant cellular proliferation, including but not limited to, malignant neoplasms and tumours, cancers (including breast cancer, non-small cell lung cancer (NSCLC) and squamous cell carcinomas (SCC) (including SCC of the head and neck, oesophagus, lung and ovary), leukemias (including acute lymphoblastic leukaemia (ALL) and chronic myeloid leukaemia (CML)), lymphomas (including acute lymphoblastic leukaemia (ALL) and chronic myeloid leukaemia (CML)), psoriasis, bone diseases, fibroproliferative disorders (e.g., of connective tissues), and atherosclerosis. Any type of cell may be treated, including but not limited to, lymphatic, blood, lung, colon, breast, ovarian, prostate, liver, pancreas, brain, and skin.

[0171] The anti-cancer effect may arise through one or more mechanisms, including but notlimited to, the regulation of cell proliferation, the inhibition of angiogenesis (the formation of new blood vessels), the inhibition of metastasis (the spread of a tumour from its origin), the inhibition of invasion (the spread of tumour cells into neighbouring normal structures), or the promotion of apoptosis (programmed cell death).

[0172] The compound of Formula (I), or a pharmaceutically acceptable salt thereof, being an inhibitor of BCL6, has potential therapeutic uses in a variety of BCL6-mediated disease states. BCL6 expression has been linked to a variety of lymphomas (Wagner et al., British J Haematology, 2010, 152, 3-12). BCL6 is involved in chromosomal translocations in diffuse large B-cell lymphoma (DLBCL) and inhibitors of BCL6 have been reported to kill DLBCL cells (Cerchietti et al., Cancer Cell, 2010, 17, 400-41 1), primary low grade follicular lymphoma cells (Cardenas et al., Clin Cancer Res, 2017, 23(4), 885-893) and Burkitt lymphoma cells (Polo et al., Nat Med, 2004, 10, 1329-1335). BCL6 is required for the formation of follicular helper T cells (Hatzi et al., J Exp Med, 2015, 212(4), 539-553), which raises the possibility that BCL6 inhibitors may be used to treat angioimmunoblastic T-cell lymphoma (AITL), in which BCL6 is strongly expressed (Cortes & Palomero, Curr Opin Hematol, 2016, 23, 434-443).

[0173] BCL6 has also been implicated in leukaemia cells which have acquired resistance to tyrosine kinase inhibitors (TKIs). TKIs typically fail to eradicate leukaemia- initiating cells, which may often cause recurrence of leukaemia after initial treatment. BCL6 has been identified as an important component of the TKI drug-resistance pathway in both Ph+ acute lymphoblastic leukaemia (ALL) (Duy et al., Nature, 201 1 , 473, 384-388) and Ph+ chronic myeloid leukaemia (CML) (Hurtz et al., J Exp Med, 201 1 , 208(11), 2163-2174). Inhibitors of BCL6 may therefore be used to treat ALL and CML in combination with a TKI.

[0174] Further non-haematological, solid tumours may be treated with an inhibitor of BCL6. BCL6 is amplified in approximately 50% of breast tumours and is expressed in many breast cancer cell lines, including triple negative breast cancer cell lines (Walker et al., Oncogene, 2015, 34, 1073-1082). BCL6 is also important for the survival and proliferation of non-small cell lung cancer (NSCLC) cells, primarily due to repression of genes involved in DNA damage repair (Marullo et al., Proc 107thAnnual Meeting AACR, 2016, Abstract nr 1271 and Deb et al., Cancer Res., 2017, Apr. 4^doi: 10.1 158 / 0008-5472.CAN-15-3052). BCL6 amplification may also be prevalent in squamous cell carcinomas (SCC) (including SCC of the head & neck, oesophagus, lung and ovary). Furthermore, inhibition of BCL6 has recently been reported to be a suitable therapeutic target for glioma and glioblatoma (Xu et al., Proc. Natl. Acad. Sci. U.S.A, 2017, 1 14(15), 3981-3986).

[0175] According to a further aspect of the specification there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use inthe treatment of haematological cancers such as lymphomas (including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL) and angioimmunoblastic T-cell lymphoma (AITL)), leukaemias (including acute lymphoblastic leukaemia (ALL) and chronic myeloid leukaemia (CML)) and multiple myeloma, and of solid tumours (including glioma, breast cancer, non-small cell lung cancer (NSCLC) and squamous cell carcinomas (SCC) (including SCC of the head and neck, oesophagus, lung and ovary)).

[0176] According to a further feature of this aspect of the specification there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in the treatment of lymphomas, including DLBCL, FL, BL and AITL.

[0177] According to a further feature of this aspect of the specification there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in the treatment of DLBCL and FL.

[0178] According to a further feature of this aspect of the specification there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in the treatment of leukaemias, including ALL and CML.

[0179] According to a further feature of this aspect of the specification there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in the treatment of solid tumours, including glioma, breast cancer, NSCLC and SCC.

[0180] According to a further feature of this aspect of the specification there is provided a method for treating haematological cancers such as lymphomas (including DLBCL, FL, BL and AITL), leukaemias (including ALL and CML) and multiple myeloma, and of solid tumours (including glioma, breast cancer, NSCLC and SCC (including SCC of the head and neck, oesophagus, lung and ovary)) in a warm-blooded animal such as man that is in need of such treatment, which comprises administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore.

[0181] According to a further feature of this aspect of the specification there is provided a method for treating lymphomas, including DLBCL, FL, BL and AITL, in a warm-blooded animal such as man that is in need of such treatment, which comprises administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore.

[0182] According to a further feature of this aspect of the specification there is provided a method for treating DLBCL and FL, in a warm-blooded animal such as man that is in need ofsuch treatment, which comprises administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore.

[0183] According to a further feature of this aspect of the specification there is provided a method for treating leukaemias, including ALL and CML, in a warm-blooded animal such as man that is in need of such treatment, which comprises administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore.

[0184] According to a further feature of this aspect of the specification there is provided a method for treating solid tumours (including glioma, breast cancer, NSCLC and SCC (including SCC of the head and neck, oesophagus, lung and ovary)), in a warm-blooded animal such as man that is in need of such treatment, which comprises administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore.

[0185] According to a further feature of this aspect of the specification there is provided the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of haematological cancers such as lymphomas (including DLBCL, FL, BL and AITL), leukaemias (including ALL and CML) and multiple myeloma, and of solid tumours (including glioma, breast cancer, NSCLC and SCC (including SCC of the head and neck, oesophagus, lung and ovary)).

[0186] According to a further feature of this aspect of the specification there is provided the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of lymphomas, including DLBCL, FL, BL and AITL.

[0187] According to a further feature of this aspect of the specification there is provided the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of DLBCL and FL.

[0188] According to a further feature of this aspect of the specification there is provided the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of leukaemias, including ALL and CML.

[0189] According to a further feature of this aspect of the specification there is provided the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of solid tumours (including glioma, breast cancer, NSCLC and SCC (including SCC of the head and neck,oesophagus, lung and ovary)).

[0190] It will be appreciated that the provisos recited in respect of the compounds of Formula I, as defined hereinabove, exclude certain compounds perse, but the use of these compounds in any of the therapeutic applications, methods and / or combination therapies defined herein is still encompassed by the present invention.Routes of Administration

[0191] The compounds of the invention or pharmaceutical compositions comprising these compounds may be administered to a subject by any convenient route of administration, whether systemically, peripherally or topically (i.e., at the site of desired action).

[0192] Routes of administration include, but are not limited to, oral (e.g, by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intra-arterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot or reservoir, for example, subcutaneously or intramuscularly.Combination Therapies

[0193] The antiproliferative treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:-(i) other antiproliferative / antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and polokinaseinhibitors); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);(ii) cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), steroid hormones, including progestogens (for example megestrol acetate) and corticosteroids (for example dexamethasone, prednisone and prednisolone), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as finasteride;(iii) anti-invasion agents [for example c-Src kinase family inhibitors like 4-(6-chloro-2,3- methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4- yloxyquinazoline (AZD0530; International Patent Application WO 01 / 94341), A / -(2-chloro-6- methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole- 5-carboxamide (das...

Claims

CLAIMS1. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as shown below:Formula (I)wherein:Xi is selected from N or CRawherein Rais selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2- 4C)alkenyl, (2-4C)alkynyl, nitro, cyano or NRbRc, wherein Rband Rcare independently selected from hydrogen or (1-2C)alkyl;X2 is selected from N or CRd, wherein Rdis selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy;R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo;Y is absent or O, S, SO, S02, N(Re), C(O), C(0)0, OC(O), C(0)N(Re), N(Re)C(0), N(Re)C(0)N(Rf), N(Re)C(0)0, OC(0)N(Re), S(0)2N(Re), or N(Re)SC>2, wherein Reand Rfare each independently selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy,carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(0)R9, C(0)OR9, OC(0)R9, C(0)N(R9)Rh, N(R9)C(0)Rh, S(0)yR9(where y is 0, 1 or 2), S02N(R9)Rh, N(R9)S02R9, Si^XR^R1or (CH2)zNR9Rh(where z is 1 , 2 or 3); wherein R9,Rhand R' are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R9and Rhcan be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring which is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano or hydroxy;R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein:^^denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rjand Rkare independently selected from hydrogen or (1- 2C)alkyl; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy;W2is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)R', S02R', C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, whereinR1and RMare independently selected from hydrogen or (1 -4C)alkyl, and wherein:R6is selected from hydrogen, (1 -2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1 -2C)alkoxy, (1 -2C)haloalkyl or (1 -2C)haloalkoxy;R7is selected from hydrogen, (1 -2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1 -2C)alkoxy, (1 -2C)haloalkyl, (1 - 2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, N(RN), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(RN), N(RN)C(0), S(0)2N(RN), or N(RN)S02, wherein RNis selected from hydrogen or (1 - 2C)alkyl;L2 is absent or (1 -2C)alkylene; andZ2is hydrogen, (1 -6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 - 4C)haloalkoxy, (1 -4C)alkoxy, (1 -4C)alkylamino, amino, cyano, nitro, hydroxy, C(0)R°, C(0)OR°, OC(0)R°, C(0)N(R°)RP, NR°C(0)RP, wherein R° and RPare independently selected from hydrogen or (1 -4C)alkyl; andR8is selected from (1 -2C)alkyl, -C(0)ORQ, ORQ, -C(0)NRQ, NRQRR, phenyl or a 5-membered heteroaryl, wherein RQand RRare independently selected from hydrogen or (1 -2C)alkyl;or R6and R7can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1 -2C)alkyl, halo, (1 -2C)haloalkyl, (1 -2C)haloalkoxy, (1 - 2C)alkoxy, (1 -2C)alkylamino, amino, cyano or hydroxyl; or(iii) a group of the formula:wherein:^^denotes the point of attachment;ring A is a 4 to 6 membered cydoalkyi or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1 - 2C)alkyl, halo, hydroxy, cyano or (1 -2C)alkoxy;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1 -2C)alkyl, (1 -4C)haloalkyl, (1 -4C)hydroxyalkyl, -C(0)-CH3or -C(0)ORabwherein Rabis (1 -4C)alkyl, R101and R102are each independently selected from hydrogen, (1 -2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1 -2C)alkoxy, (1 - 2C)haloalkyl, (1 -2C)haloalkoxy, -C(0)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, wherein Racand Radare independently selected from hydrogen or (1 -2C)alkyl; andis selected from:i) a group of Formula A shown below:Formula Awherein: denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1 -2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CFs;R10is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or O, N(RS)(CRSR 1 (where qi is 0, 1 or 2), S, SO, S02, C(O), C(0)0, OC(O), C(0)N(Rs), N(Rs)C(0), N(Rs)C(0)N(Rl), N(Rs)C(0)0, OC(0)N(Rs), S(0)2N(Rs), N(Rs)S02, wherein Rsand R< are each independently selected from hydrogen or (1-4C)alkyl; andZ3is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)hydoxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRuRvor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; andWz is aryl, heteroaryl, 4- to 7-membered heterocyclyl, 3- to 6-membered carbocycyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, 0(0)^, COORxa, C(0)NRxaRxbor NR^R^, wherein R*3and R* are each independently selected from hydrogen or (1-4C)alkyl; and wherein each aryl, heteroaryl, 4- to 7-membered heterocyclyl or 3- to 6-membered carbocycyl is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, amino, cyano or hydroxy;a group of Formula B shown below:Formula Bwherein:^^denotes the point of attachment;Xc. Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(0), C(0)0, 0C(0), C(0)N(Rw), N(Rw)C(0), NCR^C^NCR^, N(Rw)C(0)0, OC(0)N(Rw), S(0)2N(Rw), N(Rw)S02, wherein Rwand Rxare each independently selected from hydrogen or (1- 4C)alkyl; andZ5is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein:^^denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F,Xf and Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1- 2C)haloalkyl or (1-2C)haloalkoxy;Xh, X and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;with the proviso that:(i) when R3is a group of Formula B, no more than two of Xc, Xd andXeare nitrogen;when R3is a group of Formula C, no more than three of Xf, Xg, Xh, X and Xj are nitrogen;when Xi and X2 are CH, R1and R2are hydrogen or methyl, R3is a group of Formula A, Xais N, Xb is CH and R9is methyl or fluoro, R10is not a methylsulfonylaminophenyl or an aminosulfonylphenyl; andwhen Y3 is NH, each of R1and R2are not hydrogen or methyl; andthe compound is not one of the following:A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to claim 1 , wherein Xi is selected from N or CRa, wherein Rais selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, CF3, OCF3, acetylenyl, cyano or NH2.A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to claims 1 or 2, wherein X2 is selected from N or CH.A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 3, wherein Xi is CH and X2 is CH.A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 4, wherein R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl;Y is absent or O, S, SO, S02, N(Re), C(O), C(0)0, OC(O), C(0)N(Re), N(Re)C(0), S(0)2N(Re), or N(Re)S02, wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(0)R9, C(0)OR9, OC(0)R9, C(0)N(R9)Rh, N(R9)C(0)Rh, S(0)yR9(where y is 0, 1 or 2), S02N(R9)Rh, N(R9)S02R9, Si^XR^R1or (CH2)zNR9Rh(where z is 1 , 2 or 3); wherein R9,Rhand R' are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R9and Rhcan be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring.

6. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 5, wherein R1is selected from hydrogen or a group of the formula:-L-Y-Zwherein:L is absent or (1-5C)alkylene;Y is absent or O, S02, C(O), C(0)0, C(0)N(Re) or S(0)2N(Re), wherein Reis selected from hydrogen or (1-4C)alkyl; andZ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NR9RhorOR9; wherein R9,Rhand R' are each independently selected from hydrogen or (1-4C)alkyl.

7. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 6, wherein R2is selected from:(i) hydrogen or methyl;(ii) a group of the formula:wherein:^^denotes the point of attachment;Wi is selected from CR4R5or C(O), wherein R4and R5are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H or amino; orR4and R5can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from methyl, fluoro, chloro, OCH3, amino, cyano or hydroxy;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, C(O), C(0)0, OC(O),C(0)N(Rn) or N(Rn)C(0, wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl; ora group of the formula:wherein:^^denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1-2C)alkyl or -C(0)ORabwherein Rabis (1- 2C)alkyl, R101and R102are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(0)ORacor-NRacRad, and wherein Racand Radare independently selected from hydrogen or (1-2C)alkyl.

8. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 7, wherein R2is selected from:(i) hydrogen or methyl;a group of the formula:wherein:^^denotes the point of attachment;Wi is selected from CHR4or C(O), wherein R4is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H or amino;W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(0)OCH3, C(0)N(H)CH3, CR6R7R8or NR'Rm, wherein R' and Rmare independently selected from hydrogen or (1-2C)alkyl, and wherein:R6is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H;R7is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:wherein:Y2is absent or selected from O, C(0)0, C(0)N(Rn) or N(Rn)C(0), wherein Rnis selected from hydrogen or (1-2C)alkyl;L2 is absent or (1-2C)alkylene; andZ2is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano or hydroxy; andR8is selected from (1-2C)alkyl, -C(0)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rqand Rrare independently selected from hydrogen or (1-2C)alkyl; orR4and R7can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring; or(iii) a group of the formula:wherein:^^denotes the point of attachment;ring A is a 5-membered cycloalkyl or heterocyclyl ring;W3is selected from NR100or CR101R102, wherein R100is selected from hydrogen, (1 -2C)alkyl or -C(0)ORabwherein Rabis (1 - 2C)alkyl, R101is selected from hydrogen or methyl and R102is selected from (1 -2C)alkyl, hydroxy, (1 -2C)alkoxy, C(0)ORacor - NRacRad, and wherein Racand Radare independently selected from hydrogen or (1 -2C)alkyl.A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 8, wherein R3is selected from:i) a group of Formula A shown below:Formula Awherein:^^denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro,bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or N(RS)(CRSR (where qi is 0, 1 or 2), S, C(O), C(0)0, C(0)N(Rs), N(Rs)C(0), S(0)2N(Rs) or N(Rs)S02, wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 1 1-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1-3C)alkylene; andWz is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa, COORxb, C(0)NRxaRxbor NRxaRxb, wherein R"3and Rxbare each independently selected from hydrogen or (1-4C)alkyl;a group of Formula B shown below:Formula Bwherein:^^denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1-4C)alkyl; andZ5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo,(1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;a group of Formula C shown below:Formula Cwherein:^^denotes the point of attachment;R12is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3;Xfand Xgare independently selected from N or CR13, wherein R13is selected from hydrogen, fluoro, chloro, methyl, CH2F,Xh, Xi and Xj are independently selected from N or CR14, wherein R14is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy.

10. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 9, wherein R3is selected from: i) a group of Formula A shown below:Formula Awherein:^^denotes the point of attachment;Xaand Xb are independently selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R9is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;R10is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y3is absent or N(RS)(CRSR (where qi is 0, 1 or 2), S, C(O), C(0)0, C(0)N(Rs), N(Rs)C(0) or S(0)2N(RS), wherein Rsis selected from hydrogen or (1-4C)alkyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; and / or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1 -5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; andWz is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(0)Rxa, COORxa, C(0)NRxaRxbor NRxaRxb, wherein R"3and Rxbare each independently selected from hydrogen or (1-4C)alkyl;a group of Formula B shown below:Formula Bwherein:^'denotes the point of attachment;Xc.Xd and Xeare independently selected from N, CH, CF, CCI, C-CN or CCH3;R11is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:wherein:Y5is absent or O, N(RW), C(O), C(0)0, C(0)N(Rw) or S(0)2N(Rw), wherein Rwis selected from hydrogen or (1-4C)alkyl; andZ5 is hydrogen, (1 -6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1 -4C)alkyl, halo, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ryand Rzare each independently selected from hydrogen, (1 -4C)alkyl or cyclopropyl.A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 10, wherein R3is a group of Formula A shown below:Formula Awherein:^^denotes the point of attachment;Xais CH or N;Xb is selected from N or CRx1, wherein Rx1is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl;R9is selected from chloro or cyano;R10is selected from hydrogen, halo, (1 -4C)alkyl, (1 - 4C)alkoxy, (1 -4C)haloalkyl, (1 -4C)haloalkoxy, cyano or a group of the formula:wherein:Y3 is absent or N(Rs)(CH2)qi (where qi is 0 or 1),C(O), C(0)0 or C(0)N(Rs), wherein Rsis selected from hydrogen or methyl; andZ3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, 5- or 6-membered heteroaryl or 4 to 9-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-3C)alkyl, cyclopropyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(0)NRuRv, NRURVor ORu, wherein Ruand Rvare each independently selected from hydrogen or methyl; or Z3is optionally further substituted by a group of the formula:-Lz-Wzwherein:l_z is absent or a (1-3C)alkylene; andWz is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, cyano, hydroxy, (1-2C)alkoxy, C(0)Rxa, COOR"3, C(0)NRxaRxbor NRxaRxb, wherein R*3and Rxbare each independently selected from hydrogen or methyl.A compound, or a pharmaceutically acceptable salt or solvate thereof, selected from one of the following:6-Chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]- / V-methyl-pyridine-2-carboxamide;2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]- 6-methyl-pyridine-3-carbonitrile;6-chloro-5-cyano-4-[(1 ,3-dimethyl-2-oxo-benzimidazol-5-yl)amino]pyridine-2- carboxylic acid;6-chloro-5-cyano- / V-methyl-4-[[1-methyl-2-oxo-3-[(3S)-3-pyrazol-1- ylbutyl]benzimidazol-5-yl]amino]pyridine-2-carboxamide;6-chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylic acid;6-chloro-5-cyano- / V-methyl-4-[(1-methyl-2-oxo-3 / - / -benzimidazol-5- yl)amino]pyridine-2-carboxamide;6-chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-2-oxo-1-(tetrahydropyran-4- ylmethyl)benzimidazol-5-yl]amino]- / \ / -methyl-pyndine-2-carboxarTiide;Ethyl 7-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3- methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-butanoate;2-bromo-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;2-chloro-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]-6- methyl-pyridine-3-carbonitrile;5-[(2,5-dichloro-4-pyridyl)amino]-3-[(3f?)-3-hydroxybutyl]-1-methyl-benzimidazol-2- one;5-[(2,5-dichloropyrimidin-4-yl)amino]-3-(3-hydroxy-3-methyl-butyl)-1-methyl- benzimidazol-2-one;Ethyl 7-[[3-[(3 )-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;4- chloro-6-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrimidine-5-carbonitrile;5- [(2,3-dichloro-4-pyridyl)amino]-3-[(3f?)-3-hydroxybutyl]-1-methyl-benzimidazol-2- one;Ethyl 3-fluoro-7-((3-(2-hydroxybutyl)-1-methyl-2-oxo-2,3-dihydro-1 / - / - benzo[d]imidazol-5-yl)amino)pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;Methyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Ethyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Isopropyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate;Ethyl 6-chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylate;6-Chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylic acid;Methyl 3-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-propanoate;Methyl 4-[6-[(5-chloro-2-methyl-pyrimidin-4-yl)arTiino]-3-methyl-2-oxo-benzirTiidazol- 1 -yl]-2-methyl-butanoate;6-Chloro-5-cyano-4-[[3-[(3f?)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]-N-methyl-pyridine-2-carboxamide;Methyl 4-[6-[[2-chloro-3-cyano-6-(3-methyl-1 ,2,4-oxadiazol-5-yl)-4-pyridyl]amino]-3- methyl-2-oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl (2S)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate;Methyl 4-[6-[[2-chloro-3-cyano-6-(methylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl 4-[6-[[6-(but-3-ynylcarbamoyl)-2-chloro-3-cyano-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;Methyl 4-[6-[[2-chloro-3-cyano-6-(dimethylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate;6-Chloro-5-cyano-N-[2-(dimethylamino)ethyl]-4-[(1 ,3-dimethyl-2-oxo-benzimidazol- 5-yl)amino]pyridine-2-carboxamide;Ethyl 7-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1 ,5-a]pyrimidine-5-carboxylate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-hydroxy-butanoate;2-Chloro-4-[[3-(2,3-dihydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methoxy-butanoate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-ethoxy-butanoate;Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]butanoate;methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-(cyclopropylmethoxy)butanoate;2-chloro-4-[[3-(2-hydroxy-3-pyrazol-1-yl-propyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;2-chloro-4-[[3-(2-cyanobutyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyridine-3- carbonitrile;2- chloro-4-[[3-[(3S)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile;Methyl 2-[[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]methyl]cyclopentanecarboxylate;Methyl (2f?)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate;A / -[3-[6-[(2-Chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-1- methyl-propyl]acetamide;5-Chloro- / V-ethyl-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxamide;5-[[5-Chloro-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3- methyl-butyl)-1-methyl-benzimidazol-2-one;5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-1 H-pyrazole-4-carboxylate;ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrirriidiri-2-yl)-3,5-dimethyl-1 l-l-pyrazole-4- carboxylate;5-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arTiino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3,5-dihydroxy- 3-methylpentyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylpentyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(dimethylamino)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3-hydroxy-4-methoxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4- carboxamide;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-4- methoxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3,5-dihydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;1- (5-chloro-4-((3-(3-hydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;5-((5-chloro-2-(1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5- ((5-chloro-2-(4-chloro-3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;6- (3,5-dimethyl-1 H-pyrazol-1-yl)-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo- 2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)-6-methylpyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-bromo-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-methyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(5-methyl-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1 H-indazol-3-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1 H-indazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;2- chloro-4-((3-(2-(1-hydroxycyclobutyl)ethyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-(2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-2-oxo-3-(3-oxopentyl)-2,3-dihydro-1 H-benzo[d]imidazol-5- yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-((2-methyltetrahydrofuran-3-yl)methyl)-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2- chloro-4-((1-methyl-3-(2-(2-methyl-1 ,3-dioxolan-2-yl)ethyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;tert-butyl 2-((6-((2-chloro-3-cyanopyridin-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-1-yl)methyl)azetidine-1-carboxylate;5-((6-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-3-methyl-2- oxo-2,3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-(2-hydroxypropan-2-yl)-3- methyloxazolidin-2-one;1- (5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;5-((5-chloro-2-(piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(isopropylamino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-methylpiperidin-1-yl)pyrimidin-4-yl)arTiino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(ethyl(methyl)amino)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,2-dimethyl-6-(trifluoromethyl)morpholino)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl-2- 0X0-2, 3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3-methyloxazolidin-2- one;5-((6-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3- methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3- methyloxazolidin-2-one;5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl- 2-0X0-2, 3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one;5-((6-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arTiino)-3- methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one;5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-6-fluoro-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-morpholinopyrimidin-4-yl)arriino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2S,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)arriino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2R,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)arriino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(methylthio)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-bromo-5-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((3-((5-ethyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;4-chloro-6-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidine-5-carbonitrile;2-chloro-4-((3-((5-ethyl-3-methyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2- chloro-4-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((2,5-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylpentyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloropyrazolo[1 ,5-a]pyrimidin-7-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;3- (3-hydroxy-3-methylbutyl)-1-methyl-5-((2,5,6-trichloropyrimidin-4-yl)amino)-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;(R)-6-chloro-5-cyano-4-((3-(3-methoxybutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)-N-methylpicolinamide;4- ((3-(3-acetamido-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5- yl)amino)-6-chloro-5-cyano-N-methylpicolinamide;5-((5,6-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((3-(((1S,2S)-2-ethyl-2-hydroxycyclopentyl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(((1S,2S)-2-hydroxy-2-methylcyclopentyl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(1-methyl-1 H-pyrazol-3-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1 ,3-dimethyl-1 H-pyrazol-5-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,4-dimethylthiazol-5-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(thiophen-2-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(1-methyl-1 H-imidazol-2-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;2-chloro-4-((1-methyl-2-oxo-3-((4-(2,2,2-trifluoroethyl)morpholin-3-yl)methyl)-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(2-(dimethylamino)butyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-ethylpyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-2-oxo-3-((1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-(2-fluoroethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-(2-hydroxyethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(((2R,4S)-4-fluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl)methyl)-1- methyl-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-(ethylamino)butyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-3-methylhex-5-yn-1-yl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-4-methoxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-2-oxo-3-(4,4,4-trifluoro-3-hydroxy-3-methylbutyl)-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-2,3-dimethylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(3-hydroxy-3,4-dimethylpentyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2-(trifluoromethyl)morpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((3-chloro-2-fluoropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;5-((2,3-dichloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3- dihydro-2H-benzo[d]imidazol-2-one;5-((3-bromopyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro- 2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(trifluoromethyl)pyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((3-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro- 2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,5-dimethyl-1 H-pyrazol-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2-oxopyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;(S)-5-((5-chloro-2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;(S)-7-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)-5-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1 ,5- a]pyrimidine-3-carbonitrile;2-chloro-4-((1-methyl-3-(2-(2-methyloxiran-2-yl)ethyl)-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((3-(2-(3,5-dimethyl-2-oxooxazolidin-5-yl)ethyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;2-chloro-4-((1-methyl-3-((5-methyl-2-oxooxazolidin-4-yl)methyl)-2-oxo-2,3-dihydro- 1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1-methyl-3-((1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl)methyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2- one;5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)- 1 ,3-bis(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1 ,3-bis(3- hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyrimidin-4-yl)arTiino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2,2-difluoro-7-azaspiro[3.5]nonan-7-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyridin-2-yl)-N,N-dimethylpiperidine-4-carboxamide;(R)-2-chloro-4-((3-(3-hydroxybutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)nicotinonitrile;(S)-2-chloro-4-((3-((1-(2,2-difluoroethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1 H-benzo[d]imidazol-5-yl)amino)nicotinonitrile;5-((5-chloro-2-(4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoro-3-(methoxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3R,4S)-3,4-difluoropyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-((1 R,5S)-8-azabicyclo[3.2.1]octan-8-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-((1 R,5S)-3-azabicyclo[3.2.1]octan-3-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3aR,7aS)-octahydro-2H-isoindol-2-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5- ((5-chloro-2-((3R,4S)-3,4-dimethylpyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;6- ((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1 ,3-bis(3- hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;6-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)- 1 ,3-bis(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one;5-((5-chloro-2-(8,8-difluoro-3-azabicyclo[3.2.1]octan-3-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-((1r,3r,5r,7r)-2-azaadamantan-2-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;4- chloro-6-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1 ,3- bis(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5- ((5-chloro-2-(3-(methoxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3-hydroxy-5-methylpiperidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3R,5S)-3,5-dimethylazepan-1-yl)pyrimidin-4-yl)arriino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-phenylpiperidin-1-yl)pyrimidin-4-yl)arTiino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-(4-((1 H-pyrazol-1-yl)methyl)piperidin-1-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3R,5S)-3,5-dimethylpiperidine-1-carbonyl)pyridin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidine-1-carbonyl)pyridin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2- one;5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)ami1-(2-(dimethylamino)ethyl)-3-(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H- benzo[d]imidazol-2-one;5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-(2-morpholinoethyl)-1 ,3-dihydro-2H- benzo[d]imidazol-2-one;ethyl (E)-4-(5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-2-oxo-2,3-dihydro-1 H-benzo[d]imidazol-1- yl)but-2-enoate;5- ((5-Chloro-2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-[[5-chloro-2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]pyrimidin-4-yl]arTiino]-1- (2-hydroxyethyl)-3-(3-hydroxy-3-methyl-butyl)benzimidazol-2-one;5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-1-(2,2-dimethoxyethyl)-3-(3-hydroxy-3-methylbutyl)-1 ,3-dihydro-2H- benzo[d]imidazol-2-one;1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)piperidine-4-carbonitrile;1- (5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1 H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)piperidine-3-carbonitrile;5-((5-chloro-2-(4-(morpholinomethyl)piperidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(3-(morpholinomethyl)piperidin-1-yl)pyrimidin-4-yl)arriino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyrimidin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2- one;5- ((5-chloro-2-(1-methyl-1 ,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyrimidin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2- one;5- ((5-chloro-2-(3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)arTiino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((5-chloro-2-(4-morpholinopiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-h methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one;5-((2-(4-(1 H-pyrazol-1-yl)piperidin-1-yl)-5-chloropyrimidin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1 ,3-dihydro-2H-benzo[d]imidazol-2-one; or5-((5-chloro-2-(2-(hydroxymethyl)morpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- rnethylbutyl)-1-rnethyl-1 ,3-dihydro-2H-benzo[d]irnidazol-2-one.

13. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or hydrate thereof, for use in therapy.

14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or excipient.

15. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 13, for use in the treatment of cancer.

16. A compound or a pharmaceutical composition according to claim 15, wherein said cancer is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), angioimmunoblastic T-cell lymphoma (AITL), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), multiple myeloma, breast cancer, non-small cell lung cancer (NSCLC) or squamous cell carcinomas (SCC) of the head and neck, oesophagus, lung or ovary17. A method for the treatment of cancer in a subject in need of such treatment, said method comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 12 or a pharmaceutically acceptable salt or hydrate thereof, or a pharmaceutical composition according to claim 14.

18. A method according to claim 17, wherein said cancer is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), angioimmunoblastic T-cell lymphoma (AITL), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia(CML), multiple myeloma, breast cancer, non-small cell lung cancer (NSCLC) or squamous cell carcinomas (SCC) of the head and neck, oesophagus, lung or ovary.